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Accelerated tumor cell repopulation during radiation therapy is one of the leading 
causes for low survival rates of head-and-neck cancer patients. The therapeutic 
effectiveness of radiotherapy could be improved by selectively targeting proliferating 
 
 
 
tumor subvolumes with higher doses of radiation. Positron emission tomography (PET) 
imaging with 3´-deoxy-3´-18F-fluorothymidine (FLT) has shown great potential as a non-
invasive approach to characterizing the proliferation status of tumors. This thesis 
focuses on histopathological validation of FLT PET imaging specifically for image-
guidance applications in biologically adaptive radiotherapy. The lack of experimental 
data supporting the use of FLT PET imaging for radiotherapy guidance is addressed by 
developing a novel methodology for histopathological validation of PET imaging. Using 
this new approach, the spatial concordance between the intratumoral pattern of FLT 
uptake and the spatial distribution of cell proliferation is demonstrated in animal tumors. 
First, a two-dimensional analysis is conducted comparing the microscopic FLT uptake 
as imaged with autoradiography and the distribution of active cell proliferation markers 
imaged with immunofluorescent microscopy. It was observed that when tumors present 
a pattern of cell proliferation that is highly dispersed throughout the tumor, even high-
resolution imaging modalities such as autoradiography could not accurately determine 
the extent and spatial distribution of proliferative tumor subvolumes. While microscopic 
spatial coincidence between high FLT uptake regions and actively proliferative 
subvolumes was demonstrated in tumors with highly compartmentalized/aggregated 
features of cell proliferation, there were no conclusive results across the entire set of 
utilized tumor specimens. This emphasized the need for addressing the limited 
resolution of FLT PET when imaging microscopic patterns of cell proliferation. This 
issue was emphasized in the second part of the thesis where the spatial concordance 
between volumes segmented on FLT simulated FLT PET images and the three 
dimensional spatial distribution of cell proliferation markers was analyzed. 
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1. Introduction 
1.1 Biologically adaptive radiotherapy 
According to the National Institute of Health, half of all cancer patients receive 
some type of radiation therapy during the course of their treatment. Radiotherapy is 
therefore standard care for many cancer patients. It uses different methods of delivering 
ionizing radiation to reduce the size or eradicate tumors. This is done by radiation 
induced tumor cell death, a complex biochemical process initialized by DNA damage 
produced during cell irradiation. However, all living cells are susceptible to radiation 
induced cell death. Therefore, the universal goal in radiotherapy is to maximize tumor 
cell kill while limiting the normal tissue irradiation and potential treatment-induced 
secondary effects. This can be partially achieved by utilizing complex spatial 
arrangements of radiation beams/sources that create optimal deliverable dose 
distributions, which focus the majority of the radiation dose in the tumor while sparing 
the normal tissue. However, the concept of “optimal” dose distributions is a paradigm 
that is continually evolving.  
Solid tumors are characterized by highly complex microenvironments (Figure 1), 
which create spatially heterogeneous populations of tumor cells with varying sensitivity 
to ionizing radiation1. It has been observed that most disease recurrences in locally 
advanced cancers occur in regions of the tumor that are either poorly vascularized 
(hypoxic)2, 3, or have a large fraction of actively proliferating cells4-6. Therefore, the 
radiation dose could be modulated such that the resulting optimal deliverable dose 
distribution would account for the spatially variable levels of radiosensitivity found within 
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a defined target7, 8. Computer simulation studies indicate that radiation treatments that 
are selectively targeting ‘high-risk’ tumor subvolumes with increased doses of radiation 
could potentially have better outcomes than treatments that deliver uniform doses to the 
entire tumor9-12.  
 
For selective dose escalation treatments to be efficacious, different tumor regions 
need to be accurately characterized in terms of aggressiveness and/or risk of 
recurrence based on local biological features, prior to the initiation of treatment. 
However, the majority of radiation treatments are currently planned based on x-ray 
computed tomography (CT) imaging studies (Figure 2A). Due to the physics of image 
acquisition, CT images cannot provide a detailed spatial description of the tumor 
content or heterogeneity, hence no pertinent information about the biological status of 
 
Figure 1. Overlaid immunofluorescence microscopy images from thin adjacent tissue sections (FaDu tumor 
xenograft), presenting different functional aspects of tumor microenvironment surrounding a necrotic core.  
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different tumor subvolumes is used to plan radiation treatments. The current status quo 
in CT-based treatment planning is that tumors can be regarded as masses of identical 
cells uniformly distributed within a physician-defined target volume. Under this 
assumption, it was shown that the tumor control probability is correlated with the 
minimum dose delivered to the whole tumor13, and that the maximum therapeutic ratio 
of a treatment can be achieved by maximizing the degree of uniformity in the dose 
distribution covering the target volume14, 15. After decades of clinical utilization, the 
uniform dose “optimal” distribution has become a powerful dogma in radiation oncology 
since it simplifies dose prescription and reporting, creating a robust approach to 
computing tumor control probabilities, and streamlining the accumulation of clinical 
data16. As a result, treatment planning with intentionally non-uniform dose distributions 
is not a common practice in conventional external beam radiotherapy, even if it may 
present better curative strategies10, 12. 
Until recently, clinical in vivo exploration of tumor biology has been limited to 
invasive techniques (e.g. image-guided biopsy). However, the developing field of 
molecular imaging enables non-invasive visualization of different functional or 
pathological aspects of tumor biology. Biomarker probes can be administered via 
systemic circulation. Their specific binding to tumor cells enables the visualization of 
tumor biology with high contrast using functional imaging modalities such as positron 
emission tomography (PET) among others (Figure 2B). This highly sensitive and 
quantitative imaging modality can provide the information necessary in establishing a 
direct correlation between pretreatment imaging parameters, the delivered dose 
distribution and treatment outcome17. Once specific tumor regions can be identified as 
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being at-risk of recurrence based on individual patient PET imaging data18, the 
treatment can be customized, the clinical decision consisting in properly assigning dose 
to these tumor subvolumes for treatment delivery (Figure 2C). Currently, this remains a 
subjective issue, with physicians prescribing an empirical dose boost to high-risk tumor 
regions, based on clinical experience and/or patient population data9, 19-21. 
 
The concept of biologically adaptive radiotherapy as understood in this work 
refers to external beam radiotherapy strategies where the delivered treatment is 
 
Figure 2. A. Planning CT with CT-delineated gross tumor volume. B. Fusion of planning CT and corresponding 
18F-FDG PET image with PET-delineated gross tumor volume. C. Planning contours of target volumes: pink – 
50.3 Gy; blue – 68 Gy; light blue – 72 Gy. D. Overlaid calculated heterogeneous dose distribution targeting the 
PET-delineated gross tumor volume with higher doses. Figure replicated from Troost et al.21  
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customized based on individual patient biology, including but not limited to tailoring an 
optimal dose distribution that accounts for radioresistant tumor subvolumes identified by 
functional imaging (specifically PET imaging). While many of the validation steps 
involved in the clinical implementation of biologically adaptive radiotherapy are yet to be 
taken, many clinical trials have been developed in order to make this type of 
individualized therapy available to cancer patients20, 22. As research in this particular 
aspect of radiotherapy is very active, one concept remains unchanged. In biologically 
adaptive radiotherapy using PET imaging, the spatial pattern of the tracer uptake 
observed in PET images will be utilized to derive inhomogeneous dose distributions 
delivering higher doses to regions with high tracer uptake. This strategy is based on the 
hypothesis that planning PET images are accurate spatial representations of the 
underlying targeted biology.  
 
 
 
1.2 Head and neck cancer: biology and radiation therapy 
Head and neck cancer patients include those who have tumor growths in the 
nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. Most head and neck 
cancer patients are diagnosed in advanced stages23. Because of that, aggressive 
In biologically adaptive radiotherapy using PET imaging, the spatial pattern 
of tracer uptake recorded in PET images will be utilized to derive 
inhomogeneous dose distributions delivering higher doses to regions with 
high tracer uptake. 
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treatments including radiation therapy fail to improve the 20-50% five-year survival 
rate24, 25. In a multicenter randomized trial comparing radiotherapy with concomitant 
radio-chemotherapy for advanced-stage oropharynx carcinoma, Denis et al. have 
observed that only 16% of patients receiving radiotherapy alone survived 5 years or 
more, added chemotherapy slightly improving survival (22%)25.  The introduction and 
technological advancement of intensity-modulated radiotherapy (IMRT) have 
significantly improved treatment conformity for head and neck patients, increasing 
normal tissue sparing and concomitantly raising the patient quality of life post-
treatment26. In the cited study, the patients in the IMRT arm presented with better 
salivary function of the parotid glands. Only 44% of the patients were diagnosed with 
grade 2 or worse xerostomia when compared with 76% of the patients that received 
conventional radiotherapy26. However, to date, IMRT has not improved survival of 
advanced head and neck cancer patients. A need for dose escalation was emphasized 
by the fact that most treatment failures are local, occurring within the treated volume. 
For example in a study by Studer et al. 45 out of 46 patients (16% of patient population) 
that presented with local failures at two years the recurrence was inside the treatment 
field27.  
 Accelerated repopulation of tumor cells during radiotherapy is defined either 
based on direct measurement of doubling time of clonogenic cells obtained from biopsy 
specimens or indirectly by recording the extra dose necessary to control 50% of tumors 
when prolonged treatments are utilized. Many classic studies have established that the 
rate of cell proliferation in untreated solid tumors decreases with increasing distance 
from sources of nutrients and oxygen. As cells proximal to vessels are killed by 
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radiotherapy, the levels of nutrients and oxygen available of remaining cells are 
significantly improved. This activates cell proliferation in previously quiescent cancerous 
cells, increasing the fraction of cells that are repopulating the tumor mass. Furthermore, 
it has been proposed that tumor cells that are differentiating during radiotherapy have a 
higher probability of retaining clonogenic status than cells that differentiate in normal 
conditions, and their rate of proliferation may be faster with fewer aborted cell divisions. 
Furthermore, the radiation cellular damage has been shown to activate proliferation 
mechanisms in human squamous cell carcinoma134. The treatment failures in head and 
neck cancers seem to be associated with accelerated repopulation of tumor cells during 
radiotherapy5, 28-30. Uniform dose escalation trials have shown promising results 
regarding tumor control, but also an increase of severe toxicities associated with 
irradiation of organs in close proximity of the head and neck tumors (oral mucosa, 
parotid glands, etc.)31, 32. Furthermore, the incidence of treatment-associated toxicity 
greatly depends on the volume of irradiated normal tissue26, 33. In terms of biologically 
adaptive radiotherapy, the effectiveness of the treatments can be increased at the same 
time while limiting toxicities associated with escalating the radiation doses to the entire 
tumor volume30, 34-38, by delivering escalated doses only to higher-risk tumor subvolumes 
characterized by active cell proliferation. No dose-escalation trials have been conducted 
utilizing FLT PET to guide the delivered dose distributions. However, FDG-based trials 
have shown the feasibility of such an approach20. 
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1.3 Fluorothymidine – imaging cell proliferation in head and neck cancer  
 Multiple non-invasive imaging methods have been proposed for in vivo imaging 
of cell proliferation including magnetic resonance imaging (MRI) spectroscopy39, and 
PET utilizing tracers that are incorporated into DNA: [11C-methyl] thymidine, 1-(2’-
Deoxy-2’-[18F]-fluoro-1-β-D-arabinofuranosyl)-thymine, 1-(2’-Deoxy-2’-[18F]-fluoro-1-β-D-
arabinofuranosyl-uracyl)-bromouracil, and tracers that are indirectly related to cell 
proliferation. One of these latter, 3´-Deoxy-3´-[18F]-fluorothymidine (FLT). PET with 18F 
labeled FLT has proved to be the most promising imaging modality for identifying 
proliferative areas of the tumors40. 
 FLT is currently produced only for research purposes and is under investigation 
for clinical implementation as a PET tracer for cell proliferation41. FLT is a synthetic 
thymidine analog (Figure 3). Extensive validation efforts have been devoted to 
determining the biological mechanism of FLT specific uptake in proliferating cells. 
Currently it is assumed that FLT uptake in solid tumors is determined by the enzymatic 
activity of thymidine kinase 1 (TK1), a cytosolic enzyme, with high phosphorylating 
activity during the DNA synthetic phase of the cell cycle42. 
Once incorporated in the cell, FLT can serve as substrate for TK1. Thymidine 
phosphorylation is the first step in the thymidine salvage pathway for DNA synthesis. 
By delivering inhomogeneous dose distributions targeting actively 
proliferating tumor subvolumes with increased doses, the therapeutic ratio 
of IMRT for head-and-neck patients could be significantly increased. 
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While thymidine phosphates are incorporated in DNA, FLT phosphates are not due to a 
missing hydroxyl group in their structure (Figure 3). Therefore, FLT phosphates remain 
trapped intracellularly43, providing specific high uptake in cells where TK1 is 
upregulated44, 45, such as actively proliferating tumor cells. 
 
 
 However, recent studies involving correlation of in vivo FLT uptake values (static 
and dynamic PET imaging) and TK1 expression/activity assays in patients, provided no 
direct evidence of the stated hypothesis about TK1 phosphorylation being the rate-
limiting step in FLT accumulation46, 47. New evidence suggests that the FLT uptake 
mechanism is a complex interplay between membrane nucleoside transporters 
expression and activity48-50, competitive binding of nucleoside transporters between FLT 
and endogenous thymidine51-53, and relative metabolic equilibrium between FLT 
influx/efflux and activity of TK1 and enzymes that dephosphorylate FLT43, 54. 
Nevertheless, ex vivo assays of cell proliferation obtained from surgical resection tumor 
specimens (e.g. Ki-67 labeling index) correlate with in vivo tumor uptake of FLT in a 
 
Figure 3. 3′-Deoxy-3′-18F-fluorothymidine chemical structure. The only difference from the pyrimidinic nucleotide 
is the 18F isotope replacing a hydroxyl group at the 3´ position on the ribose ring. 
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wide variety of human tumors, empirically confirming FLT as a tracer of cell 
proliferation46, 47, 55, 56. 
 
  
 
1.4 Current status of validation efforts  
Validation of any biomarker assay requires demonstration that the performance 
of the assay is suitable and reliable for the intended analytical application57. As 
mentioned in section 1.1, in biologically adaptive radiotherapy, the spatial pattern of 
tracer uptake identified on PET determines the inhomogeneous dose distribution giving 
higher doses to tumor regions with high risk of recurrence of disease. Therefore, by 
demonstrating the spatial concordance between the pattern of FLT uptake and the 
intratumoral distribution of cell proliferation, FLT PET images can be safely and 
effectively used to identify and delineate tumor subvolumes characterized by active cell 
proliferation to be used in biologically adaptive radiotherapy. Validating spatial 
concordance between the FLT uptake pattern and the distribution of actively 
proliferating cells is equivalent to demonstrating that the tumor regions that contain 
tumor cells that are actively proliferating are the same tumor regions which present 
higher tracer uptake on FLT PET images (or autoradiography images). 
Currently under investigation, FLT is a promising tracer for non-invasive 
imaging of cancer cell proliferation and could be used to identify the 
location and extent of tumor subvolumes that are actively proliferating. 
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Currently, FLT PET imaging is being proposed for utilization mainly for diagnostic 
purposes38. Specifically, its suggested uses include indication of early treatment 
response35, 56, 58, 59, and prediction of long-term treatment response to radiotherapy60, 61. In 
these diagnostic applications of PET imaging in oncology, PET data is used to extract 
metrics such as average, and/or maximum standard uptake values (SUV), that allow to 
test for the presence of the disease or to predict certain characteristics of the tumor as a 
whole. Validation of such PET imaging applications is currently conducted by 
establishing correlations between single-value SUV-based metrics characterizing in vivo 
PET tracer uptake and ex vivo pathological indices representative of the target biology 
(e.g. proliferation index) over a population of patients46, 54, 55, 62-64. Since these studies 
utilize single-value metrics, no spatial information about the pattern of FLT uptake is 
retained in the analysis. Therefore, the spatial co-localization between the 
heterogeneous PET tracer uptake and that of biological markers of cell proliferation is 
not demonstrated. Up to date, there are no published data verifying the spatial 
concordance between intratumoral distribution of FLT uptake and the pattern of tumor 
cell proliferation. 
 
 
There is no validation data demonstrating the spatial coincidence between 
areas of high uptake FLT in PET images and regions of intratumoral active 
cell proliferation. 
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1.5 Study goal 
 FLT was described as a novel PET tracer specifically designed to non-invasively 
image active cell proliferation. Its specific high uptake in proliferating cells has been 
demonstrated in vitro, but up to date there is no study validating that areas of high in 
vivo FLT uptake are spatially co-localized with areas of active proliferation in individual 
tumor specimens. In proposed scenarios where FLT PET would be used in biologically 
adaptive radiotherapy for image-guidance, validation of spatial concordance with cell 
proliferation is necessary. Many factors can affect the in vivo intratumoral uptake of 
FLT. For example, the irregularities of tumor vascular system and its structural 
deficiencies65-67 can potentially modulate the levels of FLT uptake by limiting the regional 
supply of the tracer to individual cells. Furthermore, by analyzing PET imaging from first 
principles, it is well known that there are inherent limitations to the size of the smallest 
object that this imaging modality can accurately resolve68-71. Tumor microenvironment 
presents a spatially heterogeneous distribution of viable and necrotic tissue, well-
oxygenated and hypoxic regions, proliferative and non-proliferative subvolumes. The 
variation of these biological spatial characteristics spans distances that are usually 
smaller than current inherent resolution of clinical PET scanners (Figure 4). When using 
PET imaging to guide the delivery of radiotherapy, inherent averaging effects can 
significantly alter the resulting images, making it necessary to demonstrate the spatial 
coincidence between the pattern of tracer uptake as seen in PET images and the 
pattern of the underlying biological parameter of interest. Specifically, this type of 
analysis of  can provide important information about the clinical situations where PET 
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imaging provide enough spatial information about the underlying targeted biology, and 
how can this information may be safely and efficaciously used for treatment planning for 
head and neck patients. 
The research work presented herein is an attempt to address a major gap in the 
data supporting FLT PET imaging for the specific task of radiation therapy target volume 
definition, by establishing a methodology for in vivo validation of FLT PET for 
indentifying the extent and spatial distribution of cancer cell proliferation. This proposed 
study will also provide the first available sets of experimental data demonstrating the 
spatial co-localization of the intratumoral distribution of FLT uptake and cell proliferation 
markers. 
 
 
Figure 4. Immunofluorescence microscopy image of tumor microenvironment. Squares are representative of 
different PET resolution: submillimiter resolution (750 µm) for small aperture preclinical systems; 1.5 mm 
resolution of current preclinical system Siemens Inveon; 4.1 mm resolution of current time-of-flight clinical system 
Siemens Biograph mCT. 
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1.7 Research questions 
The registration of in vivo PET images with histological samples has been shown 
to necessitate a technically complex methodology72, 73, that still does not always provide 
the accuracy needed for analysis between in vivo PET images and ex vivo pathological 
images69, 74, 75. An alternative way to evaluate the concordance between the PET tracer 
intratumoral distribution and that of its intended target is to use thin tissue sections 
obtained from a surgically excised whole tumor specimen from a patient or an animal 
injected with the tracer before the surgery. 
 
Using these tissue sections, it is possible to visualize the two-dimensional 
microscopic distribution of the PET tracer distribution using digital autoradiography 
(DAR) and the spatial distribution of relevant biological markers using immuno-
fluorescent microscopy (IFM). These high-resolution imaging modalities are described 
in detail in Chapter 2. By co-registering these data and performing statistical analysis, it 
 
Figure 5. Comparison between spatial pattern of intratumoral uptake of FLT (DAR image, left) and spatial 
distribution of cell proliferation markers (uptake of bromodeoxyuridine on IFM image, right). Images were obtained 
from adjacent tissue sections. 
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is possible to evaluate how well the PET tracer distribution depicts the spatial pattern of 
the tracer’s intended biological target (Figure 5).  
This direct spatial comparison was utilized throughout this thesis with two specific 
goals. First, to demonstrate that at a microscopic level, there is spatial concordance 
between the intratumoral FLT pattern of uptake and the spatial distribution of cell 
proliferation markers. Confirming this spatial coincidence is an important clinical goal of 
the study, since it provides direct evidence that the tracer specifically targets actively 
proliferating cells in vivo. 
 
 
 
In order to realize the potential of FLT PET for image-guidance in biologically 
adaptive radiotherapy, it is necessary to analyze the spatial coincidence between the 
regions of interest contoured from macroscopic FLT PET images and underlying tumor 
subvolumes, segmented from microscopic cell proliferation images. Therefore, the 
second aim of this thesis involved developing and demonstrating utilization for a set of 
validation tools that will eventually enable comparing FLT PET synthetic images 
obtained from stacked DAR images, to the three-dimensional spatial distribution of cell 
proliferation markers. This was done as to observe the effects that the limited resolution 
Specific Aim #1 
Analyze the spatial concordance between the intratumoral pattern of FLT 
uptake and the spatial distribution of cell proliferation markers at a 
microscopic level  
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of PET induces on the FLT images’ ability to determine the spatial extent and spatial 
distribution of proliferative tumor subvolumes.    
 
 
 
1.8 Summary of thesis 
Specific aim #1 is covered in chapters 2 and 3. Chapter 2 describes the basic 
experimental methods utilized throughout the study involving tumor models, tissue 
processing, tumor microenvironment imaging and image processing techniques. More 
important, this chapter introduces a co-registration workflow that was developed for 
aligning DAR and IFM images throughout the projects presented in this thesis. The 
utilized image registration tools and an evaluation of the registration error were 
presented in detail. In chapter 3, a novel spatial concordance analysis methodology is 
introduced. Spatial concordance between intratumoral FLT uptake pattern and cell 
proliferation at a microscopic level are presented and discussed.  
Specific aim #2 is covered in chapters 4 and 5. A method to create synthetic PET 
images from DAR images is presented in chapter 4. Chapter 5 presents a methodology 
for spatial concordance analysis between simulated FLT PET images and images of 
Specific Aim #2 
Develop histopathologic validation tools for spatial concordance analysis 
between volumes segmented on FLT simulated PET images and the three 
dimensional spatial distribution of cell proliferation markers  
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tumor cell proliferation. A limited set of results are presented for head-and-neck tumor 
xenograft synthetic PET images as an illustration of the method. 
The conclusions of the thesis are presented in chapter 6.  
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2. Comprehensive approach to co-registration of autoradiography and 
microscopy images acquired from a set of sequential tissue sections 
2.1 Introduction 
Using thin tissue sections from tumor specimens that were injected with various 
tracers, it is possible to visualize the two-dimensional microscopic distribution of the 
PET tracer distribution using digital autoradiography (DAR) and the spatial distribution 
of relevant biological markers using immuno-fluorescent microscopy (IFM). Comparison 
between these imaging sets is an often-utilized validation method showing that the 
investigated PET tracer specifically binds a targeted biological molecule/pathway.  
Autoradiography is a two-dimensional imaging modality that records the pattern 
of interactions of charged particles (or photons) emitted during decay of a distribution of 
radioactive sources. In the case of DAR, phosphor plates are the detection and 
recording medium. DAR images of the distribution of radiotracer within a thin tissue 
sample (Figure 5), is an example of “in vivo autoradiography” because the tracer was 
administered and allowed to diffuse and bind while the animal was still alive. DAR is a 
highly sensitive imaging modality, with a wide dynamic range (5 orders of magnitude), 
and presents a linear response to the activity concentration present in a sample. 
Furthermore, the tissue sample is in close proximity with the imaging plate (<20 µm). 
This is of particular importance since this study uses β-particle autoradiography. 
Energetic β decay particles present non-negligible ranges before interaction with the 
detectors. By minimizing the tissue section thickness and the distance between tissue 
and detecting media, the DAR setup ensures that the image captured by the imaging 
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plate is a high-resolution representation of the radiotracer uptake distribution in that 
particular tissue section. 
Immuno-fluorescence microscopy is a light microscopy technique that utilizes a 
fluorescent microscope to visualize the distribution of specific target molecules within a 
biological sample (Figure 5). Specific fluorescent antibodies are used to the tumor-
specific molecules/biological pathways that are investigated. By stimulating the 
fluorescent tags of the bound antibodies, a fluorescent signal is obtained and recorded 
by high-resolution digital cameras. The spatial distribution of the recorded specific 
markers is representative of the distribution of the targeted molecule or pathway in that 
particular tissue section. In this study, IFM images are utilized to obtain the spatial 
distribution of specified cell proliferation markers, among other functional aspects of the 
tumor microenvironment.  
As mentioned in the previous chapter, the first specific aim of the thesis is to 
evaluate the spatial concordance between the FLT PET tracer intratumoral distribution 
and the spatial distribution of cell proliferation markers at a microscopic level. Before 
any statistical analysis is conducted, it is important to minimize the geometrical 
misalignments between the two images obtained from different modalities, which can 
introduce unaccounted confounding effects.  
To ensure the most accurate analysis results, all images (acquired through DAR 
and IFM techniques) should be acquired from a single tissue section. Most often, this is 
not feasible due to different technical aspects of the image acquisition process. 
Consequently, several studies investigating the co-localization of a PET tracer with its 
biological target used a set of sequential tissue sections to perform DAR and 
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immunohistochemical staining/imaging to reveal multiple aspects of the tumor biology76-
78.  Therefore, beyond the difficulties of registering data from different imaging 
modalities, such data acquisition methods pose the additional challenge of co-
registration of all the images acquired from different, albeit adjacent tissue sections. 
Even though the tissue sections used are thin enough (several microns) to insure 
minimum variation of the microenvironmental parameters of interest between adjacent 
sections, tissue cutting, mounting on glass slides and chemical processing can 
introduce non-linear deformations that prevent precise co-registration of the images 
acquired from adjacent tissue sections by only using rigid affine transformations (those 
allowing only translation, rotation, and scaling) . When DAR images are part of the 
image dataset, objective co-registration of the images becomes even more difficult, as 
the information content in DAR images is drastically different from microscopy images.  
For this reason, the standard of manual affine co-registration of DAR with IFM images 
tends to be highly subjective, when based on the tissue outline. 
The purpose of the study presented here is to develop and evaluate a 
methodology for objective co-registration of histopathological and DAR images acquired 
from a set of sequential thin tumor tissue sections. The details of this study have been 
previously published in the Journal of Nuclear Medicine79.  
          
2.2 Experimental methods 
Animals and tumor models 
Human cancer cells were used to establish tumor xenografts in male athymic 
mice (NCr-nu/nu, National Cancer Institute), by bilateral flank subcutaneous inoculation 
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of 5×105 cells/site. This technique of heterotransplantation of human cancer cells into 
immunodeficient rodents is a widely accepted protocol for development of preclinical 
tumor models representative of the molecular characteristics of given human cancers. 
Head and neck squamous cancer cells were used: a human hypopharyngeal cancer 
line (FaDu) was utilized for four animals, and a laryngeal cancer line with an activating 
mutation for EGFR (SQ-20B) was utilized for another four animals. Tumor growth was 
assessed by caliper measurements and recorded every other day. Animal maintenance 
and all experimental procedures were carried out according to the protocol approved by 
the local Institutional Animal Care and Use Committee at Virginia Commonwealth 
University. 
 
Radiotracers 
For this study, autoradiography was utilized to reveal the intratumoral distribution 
18F-FLT PET tracer. 18F-FLT was produced by the Center of Molecular Imaging, Virginia 
Commonwealth University (Richmond, VA).  The synthesis followed an established 
protocol, utilizing 5´-benzoyl-2,3´-anhydrothymidine as a precursor80, 81. 14C-FDG 
(American Radiolabeled Chemicals, Inc.) was also injected to evaluate the difference in 
the intratumoral distribution between FLT and FDG for a different study. 
 
Tumor tissue collection 
When the tumors reached 10-15 mm in diameter, the animals were anesthetized 
by inhalation of a mixture of oxygen and Isofluorane. At 80 minutes before planned 
animal euthanasia a bolus injection containing pimonidazole hydrochloride 
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(Hypoxyprobe, HPI, Inc., Burlington, MA) 2.5 mg/20 g mouse, Hoechst 33342 (Sigma-
Aldrich, St. Louis, MO) 0.4 mg/20 g mouse, 37 MBq 18F-FLT, and 185 kBq of 14C-FDG, 
was administered by tail-vein injection, followed by two consecutive intraperitoneal 
injections of bromodeoxyuridine (Sigma-Aldrich) 15 mg/20g mouse, at 50 and at 30 
minutes before the animal sacrifice.  After animal sacrifice, tumors were immediately 
excised, embedded in Tissue-Tek OCT (Sakura Finetek), and frozen on dry ice. The 
tumor specimens were sectioned with a Leica CM1850 UV cryostat (Leica 
Microsystems) at 8 µm thickness. From each tumor, three stacks of at least 15 
consecutive sections were obtained from the top, the middle, and the bottom of the 
tumor specimen (≥45 sections per tumor). Each section was affixed onto a glass slide 
for staining and visualization.  
 
Autoradiography 
 One section (referred to as reference section below) was selected from each 
stack of consecutive sections and used for phosphor plate autoradiography. On these 
reference sections, registration marker dots were manually placed on the glass slide 
around the tissue section, utilizing a mixture of 1 µl 14C ink (Moravek Biochemicals), 
50 µg Hoechst, and all-purpose glue. The slides selected for DAR imaging were 
covered with a layer of saran wrap to avoid contamination of the imaging plates with 
long-lived radionuclide and exposed to phosphor plate for 4 hr. All exposures were 
conducted at room temperature. 14C standards (American Radiolabeled Chemicals, 
Inc.) were simultaneously exposed with the tissue sections. The imaging plate was read 
with Fujifilm BAS-5000 Bio-Imaging Analyzer to obtain the image of 18F-FLT distribution. 
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After the first exposure, 18F activity was allowed to decay for 1 day. Thereafter, a 4-day 
exposure was initiated, as to obtain the image of distribution for the 14C-FDG tracer. In 
the last step, another 4 hr exposure was performed to confirm the insignificant 
contribution of 14C-FDG activity to the 18F-FLT image. The resulting images were 
exported in TIFF format, at 25 µm/pixel resolution and 16-bit depth. The DAR images of 
individual tumor sections (Figure 6 A-B) were cropped from a large image of the whole 
phosphor plate containing multiple sections. The typical size of individual tissue section 
image was on average 500 by 600 pixels, at 25 µm/pixel. The DAR images were 
digitized and image intensity values were converted to actual activity (Bq/mm2). Prior to 
registration, these individual tumor section DAR images were up-sampled to 2.5 
µm/pixel using nearest-neighbor interpolation, preserving the original intensity values. 
For 18F DAR, a scaling factor was experimentally derived to calibrate the image of the 4-
hour exposure to activity concentration (Bq/mm2), based on the 14C standards.  
 
Tumor microenvironment imaging 
In order to visualize different aspects of the tumor biology, such as cell 
proliferation, hypoxia, blood flow patterns, a combination of previously described 
immunohistochemical techniques were used77, 82-84. All types of acquired IFM images are 
presented in Figure 6. For imaging of cell proliferation, two different staining techniques 
were used, tracking proliferation from different perspectives. First, the distribution of 
bromodeoxyuridine (BrdU) was investigated. The intratumoral uptake of BrdU, revealed 
the density of dividing cells (in DNA synthetic phase of mitotic cycle) in the investigated 
tissue sample. Since BrdU was injected before animal sacrifice, it was distributed via 
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systemic circulation to the tumor tissue, and was made available to the cells through the 
same pathways as the radiotracers. Therefore, BrdU was considered an exogenous 
marker of cell proliferation. The second marker of cell proliferation was the endogenous 
Ki-67 protein, upregulated in proliferating cells85. As Ki-67 is absent in quiescent cells 
(G0 phase), it can provide an estimate of the density of actively cycling cells86.  
Furthermore, the correlation between anti-BrdU and anti-Ki-67 labeling indices was 
found to be statistically significant87. 
Pimonidazole hydrochloride was used as a marker of hypoxia. Hoechst 33342 
(Sigma-Aldrich) was utilized to track the tumor blood flow and diffusion, as this 
fluorescent dye is transported through the tumor’s vasculature and preferentially binds 
to nuclear regions rich in  A-T base pairs in its diffusion path. DAPI (Sigma-Aldrich) is a 
DNA specific fluorescent probe, specifically binding to nuclear regions rich in A-T base 
pairs. This stain is applied after slide preparation, and it is aimed at revealing all nuclear 
material present in the investigated tissue sample. Therefore, the resulting staining 
distribution is indicative of the extent of the viable tissue on the respective tumor 
section.  Furthermore, the distribution of viable tissue vs. necrosis is verified by 
obtaining Meyer’s hematoxylin and eosin (H&E) stain on an adjacent section. The 
microenvironmental map is completed by the distribution of the vasculature. For this 
purpose, the CD31 endothelial marker was utilized, a surface protein found on 
endothelial cells of blood vessels, also known as platelet endothelial adhesion molecule 
or PECAM-1. The immunofluorescent histochemical processing of the tissue sections 
was automated utilizing the Ventana Discovery XT system (Ventana Medical Systems, 
Inc., Tucson, AZ). H&E staining was performed manually. 
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Because of the long exposure times necessary for autoradiography and because 
of the contact with the plastic film that can damage the tissue upon removal, the tissue 
sections used for DAR were deemed unsuitable for any further immunohistochemical 
processing. Therefore, the strategy depicted in Figure 7 was adopted: obtain DAR from 
the reference section and microenvironment information from adjacent sections.  All 
 
Figure 6. Complete coregistered image dataset for one stack of sequential tissue sections of a FaDu xenograft tumor. 
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microscopy images were acquired at 20X magnification using a motorized research 
Olympus BX61 microscope, connected to X-Cite 120PC fluorescence illumination 
system for IFM imaging, and an Applied Imaging SL50 automatic microscope slide 
loader. The automated tiled image acquisition and reconstruction process was 
controlled through the Ariol software (Genetix, San Jose, CA). All images were acquired 
at 8-bit depth and had a 2.5 µm pixel size. The typical physical size of the image was on 
average 5000 by 6000 pixels, varying with the extent of the tumor tissue. 
 
 
2.3 Image registration methods and validation 
A two-step registration approach was used as depicted in Figure 7.  For each 
individual tissue section used for data acquisition, all images obtained from this section 
 
Figure 7. Image acquisition and registration scheme. Green double arrows represent rigid point-set registration used 
for the autoradiography and Hoechst images from the reference section. Blue dashed arrows represent manual rigid 
registration of microscopy images from non-reference sections.  Red solid arrows correspond to Hoechst-based 
deformable registration. 
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were initially rigidly co-registered. Thereafter, these independent sets of rigidly 
registered images representing individual tissue sections were registered together using 
deformable registration.  
 
Rigid Image Registration – Images Acquired from the Same Section 
For the microscopy images obtained from the same tumor section, the 
adjustments needed for registration were minor, as all tissue deformations induced 
during section cutting and mounting would affect all of these images in the same way.  
Misalignments could only be induced by the automated slide placement on the 
microscope tray and, potentially, tissue shrinkage during subsequent 
immunohistochemical processing.   
To correct for these misalignments, manual rigid registration of these images was 
performed in Photoshop CS4 Extended (Adobe), based on aligning tissue boundaries 
(always visible due to the tissue auto-fluorescence or non-specific binding).  Automated 
image content-based registration was avoided since the microscopy images obtained 
from the same tissue section represented radically different characteristics and features.  
Registration of DAR with IFM images poses a different problem, as the former 
are characterized by lower resolution and lack microscopic landmarks useful for co-
registration and verification. Therefore, for the autoradiography and the Hoechst image 
acquired from the reference tissue section a different registration method was used. 
Instead of relying on the tissue outlines, a set of regular landmarks was created by 
placing 8-12 dots of 14C ink mixed with Hoechst dye, around the tissue section on the 
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glass slide.  These dots (with the typical diameter of ~0.2 - 0.5 mm) were visible on both 
autoradiography and Hoechst images (Figure 6 A-C).   
For each marker dot, a weighted center of mass was obtained for the 
autoradiography and microscopy images. Using at least six marker dots (selected 
interactively), the rigid transformation needed to align the centers of mass of these dots 
in the Hoechst image with those in the autoradiogram was obtained. The rigid transform 
of the point coordinates was calculated using a MATLAB R2010a (MathWorks) 
implementation of coherent point drift (CPD) algorithm88. The algorithm is available for 
free download for research use at: 
https://sites.google.com/site/myronenko/research/cpd. The resulting transformed image 
intensity values were calculated using linear interpolation. 
The coherent point drift algorithm is a probabilistic point set registration 
algorithm, where the alignment of two distinct point sets is solved as a probability 
density estimation problem. Specifically, the primary (stationary) point set is one of the 
data sets, while the other point set (moving) is represented as the locations of the 
centroids of a Gaussian mixture model. A mixture model is a probabilistic model utilized 
to characterize the existence of sub-populations within an overall population, without 
requiring a apriori identification of  the sub-population to which an individual observation 
belongs89. A Gaussian mixture model is a parametric mixture model represented as a 
weighted sum of Gaussian component probability densities. The Gaussian mixture 
model of the moving point set is fit to the primary data in an iterative fashion by 
maximizing the likelihood (expectation-maximization algorithm). The specific 
characteristic of this algorithm is that, for every iteration, the Gaussian mixture model 
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centroids are forced to move coherently as a group, which preserves the topological 
structure of the moving data set. The coherent point drift algorithm is accurate and 
robust in case of missing data, initialization, and presence of noise. No specific 
correspondences need to be defined between the point data sets88.  
 
Deformable Image Registration – Images Acquired From Multiple Sections 
As previously reported in histopathological image registration studies90, 91, tissue 
cutting and slide preparation induce in each collected tissue section characteristic non-
linear deformations (tissue stretching, warping, etc.).  Thus, deformable image 
registration is needed to correctly align the images obtained from  adjacent or spatially 
proximate tissue sections.   
As represented schematically in Figure 7, Hoechst IFM images were obtained 
from all tumor sections. The typical diffusion distance of Hoechst in tissue is 
approximately 100-250 µm84, significantly larger than the tissue section thickness (8 
µm).  Therefore, it was assumed that the majority of the Hoechst image features 
observed in a set of consecutive tumor tissue sections are spatially constant, as 
illustrated in Figure 8.  
 
 
Figure 8. Fragments of Hoechst images acquired from five consecutive sections showing corresponding landmark 
indicated with the white cross.   
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Correspondingly, this spatial correspondence of Hoechst staining features can be used 
to establish the deformations needed to register Hoechst images acquired from non-
reference sections to the Hoechst image of the reference section.  
To perform deformable registration of Hoechst images acquired from sequential 
tissue sections, the open source Java-based Fiji plugin bundle (implemented in the NIH 
ImageJ platform) was utilized. The Hoechst images were first rigidly registered 
employing the Register Virtual Stack Slices plugin. For the reference Hoechst image 
(acquired from the section used for autoradiography acquisition) and each of the non-
reference Hoechst images (representing adjacent tissue sections), a set of 
corresponding invariant features distributed through the area of the section was 
identified using the Feature Extraction plugin employing a multi-scale oriented patch 
feature extraction algorithm92.  Using these features as soft registration landmarks, a 
deformable image registration plugin, UnwarpJ, was employed93.  This elastic 
registration algorithm was specifically designed to handle the alignment of biological 
images. The deformation field was expressed as a B-spline model. The registered 
image smoothness was ensured by way of vector-spline regularization. The registration 
field was estimated each time through the minimization of a three parameter objective 
function containing a data term (the mean squared error between images), the error in 
mapping corresponding landmarks (soft constrain), and a regularization term.  
The derived deformable transformation was then applied to the Hoechst image 
for which it was calculated, and to all other images obtained from that particular tumor 
section.  By repeating this procedure for the rest of non-reference tissue sections, all the 
microscopy images obtained from a stack of sequential tissue sections were registered 
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to the Hoechst image of the reference section. As the latter was also registered to the 
18F-FLT and 14C-FDG autoradiography images, all microscopy and autoradiography 
images were registered together by the combination of rigid and deformable registration 
techniques as shown in the flow chart presented in Figure 7, and had a resulting pixel 
size of 2.5 µm. 
 
Image Registration Error Analysis 
Rigid Registration – Images Acquired From the Same Section 
 The minor misalignments between the microscopy images coming from the same 
image were resolved by manual registration as described above. Preliminary tests 
utilizing difference images have indicated that visual inspection of the overlap was a 
sensitive method to detect misregistrations. Misalignments as small as one pixel size 
could be detected without difficulty. Therefore, the registration error of this alignment 
process was considered to be under the observable limit of one pixel (2.5 µm), thus 
negligible.   
The accuracy of the microscopy to autoradiography image rigid registration that 
was evaluated using the marker dots created around each tumor section. Specifically, 
for each image pair, the total number of marker dots visible around the tissue was 
randomly split into a registration landmark set and a measurement landmark set. The 
rigid transformation was obtained based on the optimal alignment of the registration set, 
which always contained only four points, while the rest of the landmarks served as a 
measurement point set94. To evaluate the rigid registration error, the displacements 
between the weighted centers of mass of corresponding points in the measurement 
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point set were recorded after registration, for all of the utilized sets of images (8 tumor 
models). Multiple repetitions of the registration procedure (n=30) were performed for 
each tumor model, each time using different subsets of landmarks for registration and 
for measurement.  Mean registration error and the standard deviation were calculated 
and reported for all the measurements (N = 960). 
 
Deformable Registration – Images Acquired From Multiple Sections 
To evaluate the registration accuracy of the deformable registration for the 
images acquired from adjacent tissue sections, sets of corresponding landmarks were 
established for the Hoechst image pairs to be registered (measurement landmark 
sets)95.  To ensure objective evaluation, these landmarks had to be different from those 
utilized for the registration. Therefore, a different feature extraction algorithm, SIFT 
(Scale Invariant Feature Transform), was used to establish corresponding points in the 
two images96. To obtain a set of measurement landmarks to be used for registration 
accuracy evaluation, these initial sets of points were manually processed as to assure 
proper correspondence between the landmarks, and also their uniform distribution 
across the section area.  For each of the eight tumor models, there were 3-5 different 
pairs of Hoechst images. For each Hoechst non-reference and Hoechst reference 
image pair, a minimum of 30 corresponding landmarks were defined.    
To obtain the registration error distribution after deformable registration of the 
Hoechst image pairs, the distances between corresponding measurement landmarks in 
the target image and the registered image were recorded.  The average distance 
between the landmarks after deformable registration was reported as the deformable 
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registration error. In order to calculate a combined registration error, it was assumed 
that the observed displacement values between corresponding points after image 
registration were random and normally distributed over all measurements.  The total 
registration error was represented by its two components: rigid registration error 
(autoradiography to microscopy from the same tissue section) and deformable 
registration error (for microscopy images acquired from sequential tissue sections).  The 
total registration error was defined as the convolution of the two error components 
approximated by Gaussian distributions. 
 
2.4 Results 
The initial step in the presented co-registration procedure was the rigid 
registration of DAR and IFM images obtained from the reference section.  Figure 9 
shows image overlays representative of the point-set rigid registration results. Following 
the same procedure, the 14C-FDG autoradiography and Hoechst images were 
registered to the 18F-FLT autoradiography. 
The distribution of rigid registration error measurements is shown in Figure 10A. 
The average registration error for the rigid registration of Hoechst microscopy image to 
18F-FLT autoradiography image was Erigid,Hoechst = 30.8 µm ± 20.1 µm image registration. 
The mode of the distribution was 16.1 µm, while the maximum displacement value was 
129.1 µm. The distribution of displacement values for 14C-FDG to 18F-FLT 
autoradiography image indicated an average registration error of Erigid,autorad = 
26.4 µm ± 17.9 µm. The mode of the distribution was 9.01 µm with a maximum 
displacement value of 107.4 µm. 
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The distribution of deformable registration error measurements is shown in 
Figure 10B.  These registration errors were calculated for 3-5 different pairs of Hoechst 
images for each of the eight tumor models. The success rate of the deformable 
registration algorithm was uniform across the utilized tumor models (average error 
 
Figure 9. Transparent overlay in false colors of  14C-FDG autoradiography (red), 18F-FLT autoradiography (green), 
Hoechst (light blue). Panels A and C show images manually registered based on the observed tissue outline. Panels 
B and D present the same images after rigid point-set registration. 
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ranges from 19.73 to 25.66 µm). For each Hoechst non-reference and Hoechst 
reference image pair, we had a minimum 30 defined corresponding landmarks, for a 
total of 1057 measurements. 
   
Figure 11 presents transparent overlays of images before and after the 
deformable registration procedure. Specifically, the top row demonstrate the effect of 
applying the calculated transformation for Hoechst images, while the bottom row reveals 
the overlay of two complementary aspects of the tumor biology (hypoxia and blood 
flow), before and after the deformable registration procedure. 
The calculated error of the deformable registration was 
Edeformable = 23.1 µm ± 17.9 µm, which is similar to that reported in three-dimensional 
tissue reconstruction studies utilizing the same deformable registration algorithm95. The 
distributions of the registration errors before deformable registration (red dashed line, 
maximum error 308.3 µm) and after (blue line, maximum error 108.4 µm) are shown in 
Figure 11B. 
 
Figure 10. (A) Distribution of displacement values between corresponding landmarks after rigid point-set image 
registration (Hoechst image registered to 18F-FLT autoradiogram and 14C-FDG autoradiogram registered to 18F-
FLT autoradiogram); (B) Distribution of displacement values between corresponding landmarks: before 
deformable image registration (red dotted line), after deformable image registration (blue continuous line). 
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The total registration error was calculated as the convolution of the two error 
components:  σtotal = 2 2rigid deformableσ σ+   = 44.86 µm.   
 
 
 
Figure 11. Illustration of deformable registration results using IFM images in semi-transparent overlay. Arrows 
indicate an area highlighting how initial misalignment was corrected by deformable registration. 
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2.5 Discussion 
The aim of this study was to develop and evaluate a semi-automated approach 
to multi-modality registration of autoradiography and microscopy images acquired from 
sequential tissue sections.  While this procedure was developed specifically for 
histopathological validation of PET tracers, it can be used as a tool for any co-
localization studies involving various imaging probes, especially when the images of the 
probe distributions cannot be obtained from a single tissue section. 
Earlier studies registering autoradiography and microscopy images utilized 
manual co-registration, to the observer’s best ability.  Rigid transforms (translation, 
rotation, scaling) were applied to images in transparent overlay, followed by convolution 
with a 200 µm Gaussian kernel to minimize the effect of any remaining misalignment 
errors, and/or rebinning, where the images were resampled to 200×200 µm grid for 
pixel-by-pixel analysis76, 77. Others have implemented automated rigid registration 
algorithms, followed by image rebinning to 200×200 µm pixel size to account for the 
estimated accuracy of image co-registration78. While these approaches are considered 
acceptable, manual registration of images from different modalities even when acquired 
from a single tissue section may be prone to observer bias and lack in reproducibility97. 
Lower resolution of autoradiography images combined with the background noise can 
obscure the edges of the tissue sections enough to hinder the manual registration 
relying on aligning tumor section outlines (Figure 9A, C).  Furthermore, rebinning the 
data to the coarser pixel size with or without blurring can result in a significant loss of 
information as tumor microenvironment can change significantly on the scale of 
200 µm70, 98, 99.  Image intensity-based registration was also successfully employed using 
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cross-correlation, mutual information, and minimization of image dissimilarity97, 100.  
Nevertheless, inter-modality image registration cannot rely on image content, as to 
avoid alignment of regions that have similar content but are not co-localized.  
Landmark-based registration remains the most objective registration method for multi-
modality imaging73. 
To allow for objective three-dimensional registration of in vivo images obtained 
with MRI and PET, and ex vivo histology and autoradiography images, Humm et al. 
introduced the stereotactic system employing Teflon fiduciary markers driven into the 
tumor73.  Similar to the approach of Humm et al, the present study adopted the principle 
of creating landmarks visible on all registered images, i.e. autoradiography and 
microscopy images.  However, invasive fiducials were not used in this study, to avoid 
tumor microenvironment disruption and interference with uptake of the PET tracer101.  
The most direct way to compare the intratumoral distribution of a PET tracer to 
designated biological aspects on tumor section images would be to obtain all pertinent 
information from a single representative tissue section.  Because this is practically 
unfeasible most of the time, the images of PET tracer distribution were obtained from 
one tissue section, while the adjacent sections were utilized to acquire microscopy 
images to complete the microenvironmental map of the tumor.  The novelty of the 
proposed approach is the use of Hoechst image-based registration, where the features 
of two Hoechst images acquired from the adjacent tissue sections were used to 
establish spatial correspondence between these two tissue sections and then obtain the 
deformation needed to co-register all images acquired from these sections. As a result, 
even though the images were acquired from adjacent sections, the misregistrations 
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caused by inevitable deformations that occur during tissue processing were minimized.  
An additional novel aspect of the co-registration methodology presented here is the 
elimination of manual registration of images obtained from different tissue sections, or 
from different modalities.  In this study, we have demonstrated the feasibility of the 
proposed registration procedure and evaluated its accuracy.  
The combined registration error of microscopy images to 18F-FLT 
autoradiography images was 44.86 µm. This registration error is smaller than values 
previously reported between 100-200 µm in studies using the same general imaging 
modalities76-78, 99. Furthermore, since the registration error is smaller than the inherent 
resolution of 18F or 14C autoradiography, further studies analyzing the co-localization 
between radiotracers and targeted biological pathways will be minimally influenced by 
image registration. 
Some aspects of our methodology need discussion.  The typical size of the 
marker dots placed around tissue section using mixture of fluorescent marker (Hoechst 
33342) and the 14C ink was about 0.2-0.5 mm. This is similar or larger than the typical 
size of the structures (microenvironment features) seen in the images. However, it is not 
the marker dots but rather their weighted centers of mass that were used for registration 
of autoradiography and microscopy images. Therefore, the actual size of the marker 
dots was not limiting the accuracy of registration. However, while the autoradiography 
images are characterized by linear response and wide dynamic range (16-bit), 
fluorescent Hoechst images do not have the same dynamic ranges.  Because the point-
set registration is based on aligning the weighted centroids of the masked marker dots, 
the mentioned difference in dynamic range may potentially induce inaccuracies in 
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center of mass calculation.  However, in the study presented here this issue was 
mitigated by creating marker dots as close to circular features as possible. We have 
conducted preliminary tests using a uniform mixture of fluorescent marker and the 14C 
ink to confirm that the weighted centers of mass calculated for both autoradiography 
and microscopy images coincide in the majority of cases. 
In the deformable registration of distinct Hoechst images, the definition of 
corresponding landmarks between two images can be inaccurate. Since the landmarks 
locations are only used as soft constraints in the registration algorithm, this uncertainty 
does not affect the final registration accuracy. However, during the deformable 
registration error evaluation, the uncertainty in landmark localization contributes to the 
final reported registration error. To minimize this effect, the final measurement point sets 
defined for each Hoechst image pair were manually processed and any observed 
inconsistencies eliminated by manual removal of the corresponding landmarks. 
Finally, the study presented here has been conducted using small animal tumor 
model specimens. However, the methodology can also be applied at the clinical stages 
of PET tracer validation to confirm concordance between the pattern of PET tracer 
uptake and the spatial distribution of its intended target in patient tumor specimens. 
In conclusion, a comprehensive, semi-automated method for deformable co-
registration of autoradiography and microscopy images acquired from sequential tissue 
sections was developed and evaluated. The registration method addresses significant 
non-linear deformations induced by tissue processing, and eliminates the need for 
potentially subjective manual co-registration of multimodality images acquired from 
adjacent sections. We demonstrated that this method is more accurate than the other 
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currently available methods. The improvement in registration accuracy could further 
advance correlative studies of the microenvironmental factors governing PET tracer 
intratumoral distribution. Furthermore, it can aid the studies aimed at investigation of 
spatial co-localization of different aspects of tumor biology that can be revealed by 
combination of autoradiography and/or microscopy imaging. 
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3. Analysis of spatial concordance between the intratumoral patterns 
of cell proliferation and 18F-fluorothymidine uptake at 
microenvironmental level 
3.1 Introduction 
Using ex vivo imaging of tumor tissue sections, it is possible to obtain images of 
the intratumoral distribution of PET tracer and compare them to images of specific 
molecular markers indicative of the targeted biological pathway. Establishing spatial 
concordance between these two images provides the experimental confirmation that the 
spatial pattern of the intratumoral PET tracer distribution correctly represents the spatial 
pattern of the underlying targeted biological features. This analysis can be conducted 
utilizing many different approaches. We present one way, specifically addressing the 
issue of spatial coincidence between segmentation areas defined based on FLT 
autoradiography and positive staining areas defined on proliferation microscopy images. 
In the first chapter of this thesis, the details of multi-modality co-registration between 
DAR and IFM images were presented. Utilizing this co-registration workflow, the 
geometric misalignments between images of FLT tracer and cell proliferation marker 
uptake were minimized, allowing for an accurate spatial concordance analysis.  
Previous histopathological validation studies that sought to demonstrate the co-
localization between intratumoral PET tracer uptake and tumor microenvironmental 
markers used thin tissue autoradiography and microscopy to image the tumor 
microenvironment. The resulting images were co-registered and pixel-by-pixel intensity 
correlation analysis was employed to obtain global indicators of spatial co-localization 
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(e.g. Pearson coefficient) between the grayscale intensities in the image-pairs76-78. 
However, this type of analysis is sensitive to many factors that could significantly 
influence the results. Depending on the ratio of the size of the pixels and the inherent 
resolution of 18F autoradiography70, 102, 103, local spatial autocorrelation between adjacent 
autoradiography pixels may occur, invalidating the Pearson correlation assumption of 
independence between individual pixel values. In addition, the Pearson correlation 
coefficient is highly sensitive to the presence of noise and non-specific staining/uptake 
in both considered images (autoradiography and microscopy)104. Furthermore, while 
phosphor plate autoradiography is characterized by linear response over a wide range 
of signal intensities, the response of the immune-histochemical microscopic imaging is 
generally non-linear. Therefore, the Pearson correlation coefficient, which tests the 
strength of a linear functional relationship between the pixel intensities of two co-
registered images, may not be the optimal way to measure the spatial co-localization of 
these two signals.  
Threshold-based analysis of spatial co-localization of two image sets provides an 
alternative and more intuitive approach to demonstrating the spatial concordance 
between the microscopic pattern of 18F-FLT tracer uptake and the pattern of cell 
proliferation in images from thin tissue specimens. Since the images sets are accurately 
co-registered, overlap analysis metrics such as the Dice coefficient and analysis of 
receiver operating characteristic (ROC) curves can be used to directly assess the co-
localization of the two signals. 
By its definition, a threshold value differentiates between two mutually exclusive 
target groups within a given population. Therefore, when a threshold is applied to a FLT 
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uptake image, the result is a binary map containing positive pixels – representative of 
an area where there should be active cell proliferation, and negative pixels – where 
there should not be any proliferating tumor cells. This is a classic example of a 
dichotomous classification problem, widely encountered in computer-aided diagnostic 
systems105. When the classification is conducted with a priori knowledge of where the 
actively proliferating tumor regions are, then a contingency table or confusion matrix can 
be determined (Figure 12).  
 
 
The performance of the classification system, in this case FLT thresholding, can be 
analyzed using measures for a specific threshold value105. For each selected FLT 
uptake threshold value, the true positive fraction corresponds to the portion of correctly 
classified pixels containing active cell proliferation. Correspondingly, the true negative 
fraction represents the portion of the pixel “population” which was correctly classified as 
 
Figure 12. Example of contingency table utilized in the dichotomous classification problems presented in this study. 
The gold standard is defined based on histopathological images of cell proliferation. The classification output is 
based on the FLT uptake image intensity chosen as a threshold value. 
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not containing actively proliferating cells. The false positive fraction represents the 
group of incorrectly classified pixels as containing active cell proliferating, and the false 
negative fraction, that part of the pixels that were incorrectly classified as not containing 
cell proliferation. 
Since FLT thresholding is not an ideal classification tool for identifying the spatial 
distribution of cell proliferation, providing representative threshold-based classification 
performance metrics for single threshold values does not provide a representative 
indication of the overall performance of the classification method. In many medical 
applications, ROC curves are determined by plotting the true positive fraction 
(sensitivity) against the true negative fraction (specificity)106, for all possible threshold 
values. The calculated area under the ROC curve has been used as an estimate of how 
well the investigated classification method performed, independently of the threshold 
value. 
The Dice coefficient has been used as a similarity measure over pairs of given 
sets obtained from image segmentation69, 107, 108. It can be directly calculated based on 
the threshold-based metrics defined in the contingency table. By analyzing the Dice 
coefficient values over all possible threshold values, this measure can be used to detect 
the optimal threshold values for which the majority of the proliferative tumor subvolumes 
were detected.   
The goal of this study was to investigate the spatial concordance between the 
pattern of intratumoral 18F-FLT uptake and the spatial distribution of cell proliferation 
markers using tumor tissue obtained from small animal xenograft tumor models. By 
using Dice and ROC analysis, it can be demonstrated that high FLT uptake values are 
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within areas of active cell proliferation. Furthermore, analyzing threshold specific 
measures, the specificity and sensitivity of the proposed classification method can be 
directly evaluated for any threshold value. As mentioned in Chapter 1, this study will 
provide the first experimental data set demonstrating in vivo correspondence between 
areas of high FLT high and areas of active cell proliferation.  This spatial 
correspondence was analyzed based on two-dimensional analysis of images obtained 
from individual tumor sections from different tumor specimens. The details of this study 
have been previously published in Radiotherapy and Oncology109. 
 
3.2 Methods 
Experimental design 
 The detailed description of the experimental procedures used in this study was 
presented in the chapter 2. Briefly, head and neck tumor xenografts were developed in 
immune-compromised mice. When the tumors reached approximately 1 cm in diameter, 
animals were anesthetized. Before sacrifice, the animals were injected i.v. with a bolus 
containing the 18F-FLT radiotracer. Two consecutive intraperitoneal injections of BrdU, 
used as a marker of cell proliferation77, were administered. After sacrifice, the tumors 
were excised, frozen, and embedded in OCT. From each tumor specimen, several 
stacks of consecutive 8 µm thick tissue sections were obtained. Using one tumor tissue 
section selected from each stack, phosphor plate autoradiography was utilized to image 
the intratumoral distribution of 18F-FLT76. 14C standards were simultaneously exposed 
with the tissue sections. The DAR images were digitized and image intensity values 
were converted to actual activity concentration (Bq/mm2). 
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Following immuno-histochemical processing of the tissue sections, BrdU images 
of cell proliferation were acquired with fluorescence microscopy (Figure 13). H&E 
images were acquired.  
 
Image processing 
 The DAR and IFM images were co-registered using a combination of deformable 
and rigid registration as presented in the previous chapter, with an overall registration 
error of less than 45 µm. 
 
Figure 13. Representative microscopy images sets for the two tumor models used in this study. Top row shows 
images of blood flow and cell proliferation. Bottom row shows corresponding H&E image. 
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To define the regions of interest for the spatial concordance analysis, the extent 
of the viable tissue was delineated based on H&E images. First, any non-tumor tissue 
(muscle, lymphatic tissue) and specimen edges were removed using Photoshop CS4 
Extended tools. These corrected H&E images were processed in MATLAB, and utilizing 
color segmentation and morphological processing, the viable tissue masks were 
obtained as a subset of the whole tissue area (Figure 14).  
 
 
 
To minimize the effect of residual registration misalignments, the DAR images were 
rebinned to 50 µm per pixel, utilizing the mean intensity value for the resulting pixels. A 
different approach was adopted for the rebinning of proliferation images. In the first 
step, all non-specific staining that occurred in necrotic parts of the tissue was masked 
out using the viable tissue mask. Secondly, the corrected images were binarized 
utilizing a local Otsu thresholding method110, 111. The resulting mask was used to remove 
 
Figure 14. Viable tissue (shown in white) and necrotic areas (shown in grey) obtained from H&E images. Only the 
viable tissue is utilized for analysis. 
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all low-intensity non-specific staining inside the viable tissue, obtaining corrected 
images of cell proliferation. Since the viable tissue masks were obtained from different 
(albeit adjacent) tissue sections, manual removal of any remaining high-intensity 
staining artifacts was performed. In a final step, a global Otsu threshold was applied to 
the corrected cell proliferation images to obtain only true positive areas of BrdU staining. 
The resulting binary image was rebinned to 50 µm pixel size, so that the value assigned 
to each pixel represented the fraction of its area that was positively stained. The 
resulting image was referred to as the proliferative cell density image throughout the 
rest of the study. To preserve consistency in the analysis of the regions of interest, the 
viable tissue masks were also rebinned to 50 µm per pixel. For the purpose of image 
analysis, the BrdU-based proliferative cell density images obtained as described above 
were used to establish the ground truth images of cell proliferation. Specifically, a 
proliferative cell density threshold value was chosen such that the truth set was 
sensitive enough to include the majority of BrdU positive cells. Therefore, if the 50-by-50 
µm unit area contained more than 1% stained surface it was considered a positive. The 
resulting binary image was defined as the truth set (T). 
 
Image analysis and statistical evaluation 
   An instance of the measurement set (M) was obtained by segmenting the FLT 
DAR image. By varying the segmentation threshold from the minimum to the maximum 
DAR image intensity levels, a range of measurement sets was obtained. The overlap 
between the truth set, T, and the measurement sets was analyzed as a function of the 
threshold value. For each FLT threshold value, the intersection sets were calculated as 
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presented in Figure 12: the true positive set ( ), the true negative set 
( ), the false positive set ( ), and the false negative set (
). Using these intersection sets, the Dice coefficient (D) was calculated for each 
threshold value107, 108: 
( )
( ) ( )
, 1 1
2 2
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T M TP FN TP FP
∩
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ROC curve analysis106 was also carried out. This classic test of diagnostic 
accuracy was adapted to investigate the reciprocal relationship between the sensitivity 
and specificity of FLT segmentation correctly classifying the pixels where active cell 
proliferation occurred. The ROC graph depicts on the y-axis the ratio between the 
number of correctly classified pixels and total number of pixels for each instance of the 
measurement set, also called sensitivity (or recall): 
( )
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The x-axis indicates the ratio between incorrectly classified pixels and the total number 
of pixels, also mentioned as 1-Specificity (or false positive rate): 
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To compare the relative efficacy of this classification method for different scenarios, the 
area under the curve (AUC) was obtained. The AUC represents a significant single-
value indicator of the expected performance of segmented FLT images correctly 
representing the spatial distribution of BrdU positive cells. The AUC values are recoded 
as values between 0 and 1, where 1 represents an ideal classification result. Areas less 
than1 occur when significant false positive and false negative fractions are recorded. 
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Areas of 0.5 stand for random classification result. Good classification performance is 
indicated by values generally equal or greater than 0.7105. 
While 18F autoradiography is characterized by high imaging spatial resolution, it 
is nevertheless significantly lower than the resolution necessary to resolve microscopic 
details such as those visible in the IFM images of BrdU uptake. Therefore, partial 
volume effect results in lowering of the signal at an arbitrary location and spilling it over 
into the adjacent regions in the image. To study the influence of image resolution-
induced effects on the spatial concordance results, the BrdU images were blurred with a 
300 µm Gaussian filter as to create simulated autoradiography images. The size of the 
blurring kernel was an estimate of the 18F positron autoradiography resolution when 
imaging with phosphor plates, based on existing literature102, 103, 112. Subsequently, these 
BrdU-based simulated autoradiography images were segmented as was done in the 
case of the FLT autoradiography, and were used to obtain measurement sets in the 
threshold-based image analysis as described before. 
All statistical tests were done utilizing the Statistical Toolbox offered within the 
MATLAB R2010a package. Since the data samples were small (8 FaDu tumors, 7 
SQ20B tumors), normality of the data could not be clearly demonstrated. Therefore, 
non-parametric hypothesis testing was utilized, specifically the two-sided rank sum test 
(Mann-Whitney U test). A P value less than or equal to 0.05 was considered statistically 
significant. 
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3.3 Results 
Tumor characteristics 
Whereas both investigated tumor lines were human squamous head and neck 
cancers, they expressed different rates and patterns of growth (Figure 13). FaDu, a 
human hypopharyngeal cell line produced tumors at least twice as fast as SQ20B 
(laryngeal origin) for the same caliper-measured volume. Both tumor models present 
heterogeneous pattern of BrdU DNA incorporation across the tumor section, with higher 
uptake generally adjacent to well vascularized areas. 
ROC analysis  
The ROC analysis consists of a two-dimensional representation of classifier 
performance (FLT-positive pixel correctly classifying BrdU positive pixel) and is 
visualized within the unit square (Figure 15). Therefore, the AUC values were between 
0 and 1, with values closer to unity indicating a greater accuracy of the classification 
method. For FaDu tumors, the median value for the AUC was 0.74 with a range of 0.55-
0.84, while for SQ20B tumors the AUC median value was 0.51 with a range of 0.42-
0.69. The difference in medians was significant at 5% level. Higher values of the AUC 
provide direct evidence of the spatial concordance between the areas of increased 
activity in the FLT DAR images and the areas of increased proliferative cell density.  
A sensitivity analysis was also conducted where the variation of the ROC curves 
and AUC values was assessed as a function of the threshold value applied to obtain the 
truth set. Therefore, the measurement sets were compared against more conservative 
truth sets. These sets were obtained by increasing the minimum proliferative cell density 
value above which the resulting pixel in the truth set was positive (10% vs. 1%). For 
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FaDu tumors, the new median AUC value was 0.73 with a range of 0.5-0.84, not 
significantly different from the original value. Similarly, for SQ20B tumors, the new 
median AUC value of 0.48 (0.41-0.6), was not significantly different from the value 
calculated for 1% proliferative cell density. The AUC values were still significantly 
different between the two tumor lines. 
 
 
Dice coefficient analysis 
 For each FLT threshold level, a Dice coefficient value was calculated (Figure 16). 
The Dice coefficient values indicated the fractional amount of overlap between the 
segmented FLT area and the BrdU truth set. For FaDu tumors, the median value for the 
maximum Dice coefficient was 0.61 (range: 0.26-0.77), while for SQ20B it was 0.55 
(range: 0.44-0.69). The difference in median values was not statistically significant at 
5% level (P value = 0.31). 
 
Figure 15. Examples of ROC curve analysis for utilizing segmented FLT images to predict the spatial distribution of 
cell proliferation. Presented results were representative of the two tumor specimens presented in Fig. 2 (AUCFaDu = 
0.73; AUCSQ20B = 0.52). The diagonal dashed line (AUC = 0.5) represents the random chance line. 
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A significant difference between the median values of the FLT thresholds at which the 
maximum Dice coefficient occurred was recorded. For FaDu tumors, it was 38.5%, 
while for SQ20B tumors it was 7%. As for ROC analysis, the sensitivity of overlap 
analysis as a function of the proliferative cell density threshold value was assessed. 
Using a more conservative truth set, the maximum overlap decreased, as indicated by a 
median Dice value of 0.38 for FaDu tumors and 0.16 for SQ20B tumors. The difference 
in median threshold value at which maximum overlap occurred remained statistically 
significant between the two tumor lines, 57% for FaDu tumors, and 24% for SQ20B 
tumors. 
 
 
Figure 16. Dice overlap analysis. Presented results were representative of the two tumor specimens presented in 
Fig. 2 (DFaDu = 0.69; DSQ20B = 0.55). Arrows indicate FLT threshold level for which the maximum Dice coefficient 
was calculated for the selected tumor sections. 
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Effect of autoradiography resolution 
 To study how finite imaging resolution-blurring present in autoradiography 
images affects the results of the analyses presented above, the BrdU microscopy 
images were convolved with a Gaussian kernel of the same size as the estimated 
resolution of 18F autoradiography. 
 
 
 
These blurred BrdU images were used to create the measurement sets, while the high-
resolution BrdU images were used to determine the truth set. Whereas there was 
perfect spatial co-localization between the images used to produce the two sets used in 
the analysis, the ROC analysis indicated less than perfect spatial concordance between 
blurred BrdU and proliferative cell density images (Figure 17). FaDu models presented 
 
Figure 17. ROC and Dice analysis of blurred BrdU image vs. BrdU-derived truth set: top panel – ROC analysis 
(AUCFaDu = 0.86, AUCSQ20B = 0.59), bottom panel – Dice coefficients vs. threshold levels of blurred BrdU image. 
Arrows point to the threshold values at which the maximum Dice coefficient occurs (DFaDu = 0.79, DSQ20B = 0.56). 
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a median AUC of 0.92 (0.82-0.95), while for the SQ20B tumors the AUC was 0.7 (0.55-
0.82). In addition, the overlap analysis indicated that the median value for the maximum 
Dice coefficient was 0.77 (0.59-0.85) for FaDu tumors and 0.61 (0.49-0.72) for SQ20B 
tumors. 
 
3.4 Discussion 
The spatial concordance between intratumoral FLT uptake and the distribution of 
cell proliferation markers was studied using small animal tumors representative of 
human squamous head and neck cancers. The results presented here complement 
those of previous studies in which 18F-FLT was investigated as a tracer for PET imaging 
of cell proliferation without addressing the issue of spatial correspondence between the 
patterns of FLT uptake and cellular proliferation41, 46, 55, 113. While less important for many 
diagnostic applications of FLT PET imaging, the issue of spatial concordance is of 
utmost importance in radiation oncology treatment planning, where boundaries of the 
high PET tracer uptake region are used to define shape and extent of radiation dose 
distribution used for boosting the  patient’s high risk GTV subvolume.  
 
Experimental setup 
Some of the experimental details need further discussion. In this study, 
automated immuno-histopathological processing of the tissue and standardized image 
acquisition protocols allowed consistent results in obtaining the microscopy images. The 
necessary confidence in the truth set definition was further ensured by careful 
examination and correction of staining artifacts. In addition, Otsu thresholding has been 
 
57 
 
shown to be one of the most efficient algorithm for segmentation of fluorescent 
images111. As for the sensitivity of the truth set to the proliferative cell density value used 
to define the truth set, a preliminary analysis was conducted. ROC analysis results were 
not significantly different, indicating that the specificity of FLT segmentation was 
consistent in classifying the active proliferation areas indicated by more conservative 
truth sets. The overlap analysis indicated the expected results for a gradual decrease in 
extent of the truth set. This study was based on the observations from two tumor lines, 
utilizing specimens from 15 tumors total. By expanding the study to include more tumor 
specimens and other cell lines, will allow for further evaluation of FLT images as 
indicators for determining the spatial distribution of cell proliferation. 
 
FLT for imaging spatial pattern of cell proliferation in FaDu and SQ20B tumors 
Thresholding the FLT autoradiography was the investigated method to retrieve 
the spatial pattern of cell proliferation. As pointed out by the ROC analysis of FaDu 
tumor data, the median AUC value of 0.74 indicated that FLT segmentation was a good 
method for identifying proliferating subvolumes. In addition, this finding is a direct 
indicator that FLT high-uptake regions in the FaDu tumors are spatially concordant with 
areas of increased proliferation. Dice coefficient values varied across the range of FLT 
threshold values selected for particular instances of the measurement sets. The 
presence of a peak Dice value revealed that there were FLT segmentation values for 
which there was a maximum amount of overlap between the thresholded FLT image 
and the BrdU-defined truth set, and the true positive fraction was greater than the false 
positives. For FaDu tumors, this was achieved at a median threshold value of 38.5%.  
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For the SQ20B tumors, the maximum amount of overlap between FLT-
segmented areas and the truth set was similar, as indicated in the median value of the 
Dice coefficient (0.55). While not significantly different from FaDu data, these values 
consistently occurred for very low FLT threshold values (median of 7%). This indicates 
that for SQ20B tumors, FLT-segmented areas include a maximum amount of the truth 
set only when the majority of the intensity values were included into the segmented set 
(large false positive fraction). Since it is expected that higher intensity values be co-
localized with the areas of active proliferation, this result provides direct evidence of the 
lack of specificity in retrieving the spatial pattern of cell proliferation. ROC analysis also 
supported this finding, where the median AUC value was 0.51. The low AUC value 
(representative of random chance in ROC analysis) indicates that for this tumor type, 
the areas of increased FLT uptake were not spatially concordant with the areas of 
increased proliferation. 
 
Tumor morphology 
The results obtained for the SQ20B tumor model were unexpected. The 
experimental methodology was identical for the both head-and-neck tumor models. The 
only fundamental difference between them that could explain the observed differences 
was in their pattern of growth and the resulting distribution of microenvironmental 
features. The faster growing FaDu tumors, presented a highly compartmentalized 
spatial pattern of cell proliferation (Figure 13). There was uniform BrdU uptake all 
throughout the well-vascularized area, creating a proliferating rim surrounding hypoxic 
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and necrotic tumor regions. In contrast, a slow, lobular type of growth induced a 
dispersed uptake pattern of BrdU in the SQ20B models. 
 
Imaging resolution 
Since the microscopic features observed in the cell proliferation images were on 
a smaller scale than the autoradiography resolution, it was necessary to investigate the 
direct effect of finite imaging resolution on the spatial concordance results. This was 
done with the aid of the BrdU images blurred with the kernel simulating the resolution 
limitation of autoradiography images. Thresholding of the blurred BrdU image was less 
specific at retrieving the spatial pattern of original BrdU staining distribution in SQ20B 
tumor xenografts, than in the FaDu tumors (Figure 17). Since the same blurring kernel 
was applied to both tumor models, this effect could only be caused by the degree of 
heterogeneity in the spatial distribution of cell proliferation. The SQ20B tumor models 
had a more dispersed distribution of proliferation markers. Correspondingly, blurring 
affected these tumors more so than the FaDu tumors, which had a more 
compartmentalized distribution of cell proliferation. For the latter tumor model, the 
typical size of the actively proliferating ‘‘compartments’’ was similar or larger than the 
resolution of autoradiography, therefore blurring did not affect their general spatial 
distribution. On the other hand, for the SQ20B model, there was no clear 
compartmentalization of proliferation. After blurring, the typical size of the observed 
features was significantly larger than of those seen in the original BrdU microscopy 
image. 
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FLT-based delineation of actively proliferating tumor subvolumes 
When applying the tumor-specific median value for the FLT threshold that 
produced the maximum overlap between areas of increased proliferation and 
segmented FLT area, the results were indicative of the difference between the two 
tumor lines. As emphasized with the blue contour line (Figure 18), the regions 
delineated on SQ20B tumors coincided with the whole tissue section area in the 
majority of cases, while for the FaDu tumors the actively proliferating “compartment” 
was correctly delineated. To visualize the possibility of misinterpretation of segmented 
FLT regions, the 50% of maximum intensity threshold value was utilized for images from 
both tumor lines (red contour, Figure 18), as a global threshold that is commonly utilized 
for FLT PET segmentation35, 114. There were distinct areas delineated on both tumors. 
This threshold value resulted in segmented areas that were more conservative, but 
which were still spatially concordant with areas of increased cell proliferation in FaDu 
tumors. At the same time, the segmented areas significantly underestimated the extent 
of the cell proliferation in the SQ20B tumors. 
 
Spatial concordance of FLT uptake and cell proliferation 
As illustrated by the xenograft tumor data presented above, tissue morphology 
and the resulting spatial heterogeneity of cell proliferation, together with finite imaging 
resolution, significantly affect the feasibility of using 18F-FLT DAR images to specifically 
predict the spatial distribution of cell proliferation, as imaged with BrdU. This directly 
affected the study conclusions about the generality of FLT spatial concordance with cell 
proliferation. While for FaDu tumors spatial concordance was clearly supported by the 
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data acquired, the same cannot be said about SQ20B tumors. However, this does not 
imply that there is no spatial concordance between FLT uptake and cell proliferation in 
both of the tumor models at a cellular level. The experiment with the blurred BrdU image 
confirmed that the spatial concordance analysis for SQ20B tumors is inconclusive due 
to the mentioned combined effect of imaging resolution and spatial proliferation pattern 
heterogeneity. The dispersed pattern of cell proliferation imaged in these tumor samples 
could not be resolved by autoradiography with 18F. As a result, the overall high tracer 
uptake across the tumor section correctly indicated the ubiquitous presence of active 
cell proliferation throughout the tissue section specimen. Nevertheless, the noise 
associated with 18F autoradiography and the overlap of the “spill-off” regions 
corresponding to each cell containing the tracer, made it such the high-activity regions 
recorded in the autoradiographic image did not coincide with the location or the extent 
of the imaged spatial pattern of cell proliferation. Depending on the tumor-to-
background uptake ratio while imaging in vivo, FLT PET may correctly determine that 
for tumors such as SQ20B, the whole tumor is actively proliferating. Nevertheless, this 
aspect needs further analysis.  
 
Conclusion 
In this study, autoradiography images were utilized for the delineation of distinct 
tumor subvolumes of increased cell proliferation. The results indicate the difficulties in 
this process present even when utilizing autoradiography imaging, which is 
characterized by the resolution superior to that of any small-animal PET or clinical PET 
scanners. In PET imaging, the averaging effect induced by positron travel alone can 
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significantly reduce the ability of FLT uptake images to correctly reproduce any map of 
cell proliferation. It seems that as long as the compartmentalization of the tumor 
microenvironment presents features that can be resolved with the employed imaging 
modality, subvolume delineation is feasible. 
 
These observations agree to other studies investigating the ability of 18F-FDG69 
or 18F-FAZA70 to reproduce the intratumoural distribution of their intended biological 
target. Further studies of the spatial concordance between the actual intratumoural 
 
Figure 18. Tumor subvolumes delineated based on thresholding 18F-FLT autoradiography. FLT threshold contour 
(iso-intensity) lines were then superimposed on BrdU microscopy images. 
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pattern of FLT uptake in PET images and the spatial distribution of cell proliferation in 
human pathological samples could elucidate the situations in which imaging with this 
particular tracer could provide useful information on the spatial distribution of actively 
proliferating cells. 
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4. PET simulation 
4.1 Introduction 
 In chapters 2 and 3, the first specific aim was addressed. Specifically, the spatial 
concordance between FLT uptake pattern and the spatial distribution of cell proliferation 
was analyzed at a microenvironmental level. The microscopic uptake of FLT was 
imaged with DAR, while the pattern of BrdU uptake represented a surrogate for the 
spatial distribution of active cell proliferation. It was observed that when tumors present 
a pattern of cell proliferation that is highly dispersed throughout the tumor, even high-
resolution imaging modalities such as DAR could produce incorrect predictions about 
the extent and spatial distribution of proliferative tumor subvolumes. While spatial 
coincidence between high FLT uptake regions and actively proliferative subvolumes 
was demonstrated in tumors with highly compartmentalized/aggregated features of cell 
proliferation, there were no conclusive results across the utilized tumor lines. This 
emphasized the need for histopathological validation of FLT PET imaging for image-
guidance applications in radiotherapy. 
In most diagnostic applications of PET imaging in oncology, PET data is used to 
extract metrics such as SUVaverage, SUVMAX, or SUVpeak that allow to test for the 
presence of disease or to predict characteristics of the tumor as a whole. Validation of 
such PET imaging application can be done by establishing the correlation between 
single-value SUV-based metrics characterizing in vivo PET tracer uptake and ex vivo 
pathological indices representative of the target biology (e.g. proliferation index) over a 
population of patients46. 
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However, when PET imaging is used for radiation therapy guidance, e.g. to 
identify aggressive tumor subvolumes that can be targeted with selective dose 
escalation, it is the spatial characteristics of the PET images that are used to define the 
treatment dose distribution. Correspondingly, validation of PET imaging for radiation 
treatment planning requires an approach that allows testing the spatial coincidence of 
the region of high tracer uptake, as imaged with PET, and the biological/morphological 
features of interest. The gold standard for validating PET imaging for radiotherapy 
image guidance is histopathological validation, whereby non-invasive PET images are 
registered to ex vivo histopathological images enabling the analysis of their spatial 
association. Unfortunately, the required registration of PET and histopathological data is 
a subjective process that is prone to error. Furthermore, the registration is not always 
feasible due to the significant deformation of the specimen after the surgical excision. 
Several groups have reported experimental methods for high-precision co-registration of 
histopathological images with in vivo PET images from small-animal models achieving a 
registration error of less than 0.3 mm. However, these methods either necessitate 
invasive fiducials that can alter the tracer uptake73, or require embedding the animal in 
liquid molds72, 115, which can potentially interfere with normal animal physiology and 
prohibit their adaptation to human validation studies. 
Various surrogate histopathological validation techniques involving human 
specimens have been developed to test the accuracy of PET-based gross tumor 
volume delineation. In these studies, in vivo PET images are segmented utilizing 
selected thresholding protocols and either segmentation volumes or their largest 
diameter is compared to those of surgically resected tumor specimens116-118. While good 
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correspondences were reported between PET-derived metrics and those obtained from 
ex-vivo imaging, the methodology used in these studies does not provide the spatial 
information necessary for the analysis of the spatial correspondence between the PET 
tracer distribution in tissue and corresponding biology119, 120.  
In this study, an alternative method for histopathological validation of PET 
imaging for radiotherapy image-guidance applications is presented. This method 
circumvents the problems associated with the registration of in vivo PET images with 
microscopic histopathological images. The approach is demonstrated using small-
animal tumor models. However, the method is equally applicable to the clinical PET 
imaging validation using whole-tumor specimens of human origin. 
Utilizing whole tissue specimen sections, autoradiography was used to obtain 
images of the microscopic distribution of the PET tracer. Tumor microenvironment and 
morphology images were obtained from the same locations. Using the reconstructed 
tracer 3D distribution, realistic synthetic PET (sPET) images were obtained. Monte-
Carlo models of clinical and research PET scanners exist in literature121-124 and they can 
be used to perform accurate simulations of all physical processes contributing to PET 
image formation and to arrive to sPET images that are representative of a given 3D 
microscopic tracer distribution. However, as a proof of principle, a simplified approach to 
PET image simulation was utilized in this study, where sPET images were obtained by 
convolution of the intratumoral tracer distribution with a 3D kernel representative of the 
spatial resolution of a small-animal PET scanner.  
By virtue of their generation, sPET images are perfectly registered to the 
underlying autoradiography data that in turn can be precisely registered to the 
 
67 
 
histopathological images of tumor microenvironment79. Therefore, the resulting sPET 
image sets can be used to study the spatial concordance between the pattern of the 
tracer uptake as depicted in PET images and underlying microenvironment, without the 
confounding effects of registration uncertainties. 
4.2 Methods 
Tumor Models and Radiotracer 
As before, human head and neck tumor xenografts (SQ20B) were developed in 
male athymic mice (NCr-nu/nu; National Cancer Institute), from bilateral flank 
subcutaneous inoculation of 106 cells/site. Animals were maintained according to the 
protocol approved by the Institutional Animal Care and Use Committee at Virginia 
Commonwealth University. The PET simulation and tracer validation process was 
demonstrated using a different tracer from FLT, as to demonstrate its versatility. 14C-
labeled 2’-Deoxy-2’-[F]fluoroglucose (American Radiolabeled Chemicals, Inc.) was 
utilized as the investigated tracer. This compound is chemically identical to the clinically 
utilized 18F-FDG, and it was utilized for the autoradiography resolution advantage that 
the 14C β- low-energy decay particle offers. 
 
Tumor Tissue Collection 
After the tumors reached 1 cm in diameter as measured by caliper, the animals 
were anesthetized with a mixture of oxygen and isoflurane. At 80 min before planned 
animal euthanasia, a bolus injection containing Hoechst (0.4 mg/20-g mouse), and 925 
kBq of 14C-FDG was administered by tail-vein injection. After animal sacrifice, tumors 
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were immediately excised. The entire surface of the exposed tissue was coated with 
Davidson Marking System black ink (Bradley Products, Inc.), and then embedded in 
OCT. 
For embedding, a special jig was built (Figure 19A), which was similar to a 
previously reported prototype. Specifically, parallel holes were drilled in two rigid plastic 
boards (6 mm thickness). Their spacing and diameter was chosen such that they would 
fit 18G needles (BD Biosciences) in such a way as to allow a tumor specimen to fit in 
between the needles. The needles were first inserted into the bottom plastic plate, then 
through a disposable plastic mold used for specimen freezing. The excised tumor was 
positioned in the mold containing the OCT, between the needles. Then, the top plate 
was placed on top of the mold, allowing the needles to go through. After the assembly 
was tightened with screws, it was placed on dry ice for freezing. After the OCT 
solidified, the needles were retracted and the tumor specimens were sectioned with a 
Leica CM1850 UV cryostat (Leica Microsystems) at 8-µm tissue section thickness and 
mounted on glass microscope slides. 
During cutting, a stack of 3-4 consecutive tissue sections was collected every 
120 µm throughout the specimen. In addition, for every sequential stack of tissue 
sections, a digital image of the cutting plane was acquired utilizing a Pentax Optio S7 
digital camera in macro mode employing a remote trigger. The camera was mounted on 
a custom-built plastic frame that fitted the cryostat work-window (Figure 19B). The 
double ball-in-socket adjustable locking mount (Ram Mounts Cat# RAM-B-202AU, 
RAM-B-201U, RAM-B-202U, National Products, Inc.) allowed for an accurate alignment 
of the camera optical axis with the axis of the specimen holder, perpendicular to the 
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cutting plane. Once camera position was selected, the joints were locked in place, 
ensuring the reproducibility of the position from which the digital image of the tissue 
block was taken (Figure 19C).  
 
 
 
Tissue Imaging 
One section from each image stack obtained at every sampling location was 
used for autoradiography. The sections covered with a thin plastic wrap (<20 µm) were 
placed in contact with the phosphor plates in light-tight cassettes for 5 days at room 
temperature. The imaging plate was read with Typhoon 9410 Variable Mode Imager 
(GE Healthcare) to obtain images of the FDG distribution (Figure 20B). The reader 
output was digitized in grayscale TIFF images with 25 µm pixel size. The grayscale 
intensities were converted to activity concentration based on the images of 14C 
standards that were co-exposed with the tissue sections to the same imaging plates. 
 
 
Figure 19. A. Freezing jig for tissue specimen. B. Cryostat setup with mounted camera on double-jointed adaptor. 
C. Example of the tissue specimen digital photo with hollow columns as registration fiducials. The margins of the 
tissue were inked to increase the contrast of the tissue boundary. 
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Since the tissue utilized for autoradiography becomes dehydrated and can be 
damaged during plastic film removal, adjacent tissues were utilized to image the desired 
aspects of tumor morphology and/or microenvironment. For this study, H&E staining 
was performed on the tissue section adjacent to the section used for autoradiography. 
Any other relevant stain (e.g. hypoxia, proliferation, apoptosis, vasculature, etc.) can be 
carried out as well. The H&E microscopy image was deformably registered to the 
autoradiography image from the same stack using the methods described in chapter 2. 
The H&E images were utilized to define the extent of the tumor tissue (whole tissue 
mask) and the subset corresponding to the viable tumor tissue (viable tissue mask) 
(Figure 20A). This was done via MATLAB R2010a script utilizing the Image Processing 
and Statistical Toolboxes. The script was an adaptation of a color-based segmentation 
algorithm using K-means clustering, presented on the MathWorks site 
(http://www.mathworks.com/products/image/demos.html). The results of the viable 
tissue segmentation were reviewed by a pathologist to confirm validity.  
 
Figure 20. Tumor B images. A. Microscopy image of hematoxylin and eosin staining. Image was acquired at 20x 
using a motorized research Olympus BX61 microscope. B. Autoradiography image. C. Simulated PET image 
slice. Both B and C images were normalized to the maximum activity value in the whole tumor. All images are at 
the same scale. 
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3D reconstruction 
 In order to reconstruct the 3D spatial distribution of the intratumoral FDG uptake 
along with the 3D distribution of the viable tissue, a two-step process was utilized. First, 
the digital photo images of the cutting plane containing the inked tissue specimen 
(Figure 19C) were rigidly registered using the visible hollow needle tracks. The 
photographic images were then re-binned as to match the pixel size of the 
autoradiography images. In the second step, the pairs of already registered 
autoradiography and the viable tissue images from each sampling location were co-
registered to their corresponding aligned digital photos. Since non-linear deformations 
occur during tissue cutting and mounting, it was necessary to use deformable 
registration for this step. Both autoradiography and H&E images are very different from 
the digital photos of the tissue. Therefore, intensity-driven or internal landmark-based 
registration strategies were not feasible. A contour-based deformable registration was 
utilized instead. The contours, represented by point-sets corresponding to the tissue 
boundaries (which remained intact during tissue section transfer onto the glass slide), 
were extracted from both digital photo and H&E microscopy image. A deformable 
transformation was obtained by aligning the contours, which was then applied to the 
autoradiography and viable tissue mask. Both registration steps were implemented in 
MATLAB R2010a using the rigid and non-rigid applications of the coherent point drift 
algorithm88. 
 At the end of the registration process, all images were stacked into three-
dimensional matrices, and rebinned at 50×50×120 µm per voxel utilizing the mean 
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values, in order to eliminate any residual misalignments after image registration. The 
resulting autoradiography stacked volume was analyzed for three-dimensional 
consistency. Consistency was defined in terms of smoothness the signal between 
consecutive slices101. Specifically a normalized correlation coefficient was calculated 
between each pair of consecutive slices, and the mean and standard deviation of the 
correlation coefficients was reported as a measure of the 3D consistency of the 
reconstructed volumes. 
The error of the rigid registration of the digital photo images was measured in a 
separate experiment. Instead of a tumor specimen, a suture filament was tensioned in 
the tumor mold and embedded as presented above. The block was sectioned and the 
digital photo images were obtained and registered as before. The 3D coordinates of the 
suture filament in each section were detected. Utilizing linear regression, a line was 
fitted through the points such that the perpendicular distances from the data to the fitting 
model were minimized. The mean and standard deviation of the residual projection 
distances between fit model and data points were reported as the registration error.  
  
PET simulation 
 The simulated PET image was obtained by convolving 3D autoradiographic data 
sets with the 3D point-spread-function kernel of the Siemens Inveon small-animal PET 
scanner (Siemens Medical Solutions, Inc.) using MATLAB R2010a (Figure 20C). The 
line-spread-function was measured utilizing a custom-built water-equivalent phantom 
containing a line source. The line source was a mouse tail-vein catheter (Braintree 
Scientific, Inc.), with an inner diameter of 0.17 mm, filled with 26.6 MBq/ml of 18F 
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solution. The PET scan setup was replicated according to NEMA recommendations for 
spatial resolution measurement125. The point-spread-function in each dimension was 
derived from the Gaussian fits of the line profile126. The results obtained in-house were 
consistent with previously published data127, 128. 
 
Spatial concordance analysis 
For this study, FDG was chosen as an example of a PET tracer under validation. 
The spatial coincidence between the areas of high FDG uptake in the sPET images and 
the spatial distribution of the viable tissue, as defined based on H&E segmentation 
(Figure 20A), was analyzed utilizing overlap analysis (10). For each activity value found 
inside the volume defined by the whole tumor mask, the sPET image was thresholded 
obtaining a distinct segmentation 3D volume.  These 3D tumor subvolumes were 
compared to the H&E-based viable tissue delineation (ground truth), and different 
intersection sets were obtained: true positive, true negative, false positive and true 
negative sets108. Based on these, Dice coefficient values were calculated to determine 
the spatial overlap between segmented volumes from sPET images and the viable 
tumor tissue at each threshold value. Receiver-operating-characteristic (ROC) curves 
were utilized to evaluate the overall performance of FDG segmentation at classifying 
pixels as viable or non-viable. The area under the curve was used as a measure of how 
well FDG thresholding determines the spatial extent of the tumor viable tissue. As the 
purpose of this study was to introduce a novel methodology for PET imaging validation 
for image-guidance in radiotherapy, the ability of FDG sPET to identify viable tumor 
tissue was used as an illustration only. 
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4.3 Results 
Comprehensive sampling of the tumor tissue throughout the specimen is 
essential to the presented methodology. For the two SQ20B tumors (denoted A and B) 
that were utilized in this experiment, the total number of 4-section stacks were 41 and 
48. The recorded time stamps on the digital photos indicated that for an experienced 
user, one 4-section stack could be consistently obtained every two minutes (120 µm 
inter-stack distance).  
 
 
 
3D reconstruction and PET simulation 
The registration error of the rigid registration step in the reconstruction procedure was 
6.56 ± 4.78 µm. Figure 21 depicts orthogonal slices though the reconstructed 3D FDG 
 
Figure 21. Orthoslices through tumor B. All images are normalized to the maximum tumor activity registered in 
the aligned autoradiography stack. Color bar indicates [0, 1] range. 
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autoradiography image-set, confirming the three-dimensional coherence of the set. This 
was also confirmed by an analytic measure of 3D consistency of the analyzed sets. The 
mean and standard deviation of the normalized intensity correlation between pairs of 
successive slices in the restacked autoradiography volume presented high correlation 
values 0.84 ± 0.05 (range: 0.73-0.91) and 0.94 ± 0.02 (0.86-0.97). 
The sPET images were obtained by direct convolution of the reconstructed 3D 
autoradiography data was with a 3D Gaussian kernel representative of the point spread 
function of the Siemens Inveon small-animal PET scanner, as measured at the center of 
the scanner’s field of view: 1.56 mm tangential FWHM, 1.62 mm radial FWHM, and 2.12 
mm axial FWHM. Figure 20C presents a slice through the resulting sPET image set at 
the location corresponding to the autoradiography image presented in Figure 20B. As 
can be seen from the image, application of the 3D blurring kernel changes the image of 
the tracer uptake dramatically. The Dice overlap between the volumes obtained by 
thresholding of both sPET data set and the actual activity map reconstructed from 
autoradiography (the threshold set at 70% of maximum activity in both cases) was 0.0 
and 0.1 as measured using Dice coefficients for tumor A and tumor B, respectively. 
These values increased to 0.02 and 0.34 for the threshold set at 50% of the maximum 
activity; 0.28 and 0.47 at 30% threshold, and 0.87 and 0.79 for 10% threshold. The 
difference between sPET and 3D autoradiography is illustrated in Figure 22, which 
shows 3D rendering of the thresholded volumes. 
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Spatial concordance between the FDG uptake pattern and viable tissue distribution 
Figure 22B depicts the distinct tumor segmentation subvolumes resulting from 
sPET image thresholding performed using different activity values. To evaluate the 
classification performance of the thresholding operation performed on FDG sPET 
images as a method of viable tissue delineation, the area under the ROC curve (AUC) 
was computed as a single metric indicative of the performance of the investigated 
classification method. The results show that FDG segmentation is a good classifier for 
voxels containing viable tissue: AUCA = 0.74 and AUCB = 0.81, confirming that regions 
of higher FDG uptake are spatially co-localized with regions of viable tissue within the 
tumor. 
 
 
Figure 22. Rendered tissue outline with segmentation volumes. A. 3D reconstructed autoradiography. B. sPET. 
Threshold values represent percent of maximum intensity. 
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The maximum overlap between the FDG segmented volumes and the viable 
tissue subvolume as indicated by Dice coefficient values, was 0.8 for tumor A (at 22% of 
max intensity) and 0.88 for tumor B (at 14% of max intensity). FDG segmentation was 
highly sensitive at determining the extent of the viable tissue at these thresholds (true 
positive fraction, tumor A: 0.94, tumor B: 0.99), but it was not specific (true negative 
fraction, tumor A: 0.17, tumor B: 0.36). Figure 23 presents a sequence of viable tissue 
masks from tumor B, with overlaid iso-intensity lines obtained from the corresponding 
sPET image set. The segmentation volumes from which the iso-intensity lines were 
extracted covered the viable tissue for tumor A and tumor B respectively: 5.8% and 
3.4% at 70% of maximum intensity, 39.6% and 27.9% at 50%, 84.2% and 81.4% at 
30%, and 99.8 and 100% at 10% of maximum intensity. 
4.4 Discussion 
 Our novel method of histopathological PET imaging validation does not require 
registration of in vivo PET data with histopathological images, a step prone to error and 
 
Figure 23. Three sequential sections through tumor B, presenting viable tumor tissue (white) as a subset of the 
whole observable tissue (gray). The colored lines present iso-intensity lines from the sPET image sequence. 
Thresholds are percent of maximum intensity. All images are at the same scale. 
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subjectivity. Instead, the whole tumor specimen is used to obtain both histopathological 
data and the intratumoral distribution of the tracer that is subsequently used to generate 
a synthetic PET image. In this manner, all confounding factors associated with the 
registration of PET images to histopathological images are bypassed. Therefore, the 
only registration errors with potential effects on the spatial concordance analysis are the 
residual misalignments encountered between autoradiography and microscopy images 
obtained at each tumor sampling location (less than 45 µm).  
Currently, a number of PET tracers targeting different aspects of tumor biology 
are being developed38, and new PET-based dose escalation clinical trials 20, 22 have 
been proposed and conducted.  
 
3D reconstruction 
 The tissue processing workflow is highly adaptable and inexpensive to implement 
for a wide range of microtomes, for frozen specimens. Different jigs can be built for 
different tumor sizes using readily available materials. Similarly, the camera mount can 
be adapted to multiple microtome geometries, and any compact digital camera with 
remote trigger can be utilized. While there are institutions with highly specialized 
infrastructure for 3D tissue reconstruction94, the method presented in this study meets 
the demands of the validation goal: to obtain a 3D intratumoral distribution of a PET 
tracer that can be used to generate sPET images precisely registered to 
histopathological data. The 3D morphology of FDG uptake demonstrated good spatial 
correlation between neighboring slices, even though a non-negligible inter-slice distance 
was utilized 
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 Histology studies have demonstrated that tumor vascular tree is the main factor 
affecting the shape and location of spatial gradients of the tumor microenvironment 
functional aspects such as hypoxia or cell proliferation65, 82-84, 98. Consequently, tumor 
microenvironmental architecture is characterized by a typical spatial scale between 
50 µm and 250 µm. Therefore, the chosen distance of 120 µm between sampling 
locations ensured that all major spatial features of different aspects of the tumor 
microenvironment were properly sampled, allowing for a coherent representation of 3D 
spatial distributions of tracer activity (Figure 21) and viable tissue, as well as any other 
tumor microenvironmental parameter (e.g. hypoxia, cell proliferation, etc.).  
 
PET simulation 
The most accurate approach for creating sPET images would be a Monte Carlo 
simulation of the PET image formation starting with a 3D autoradiography microscopic 
tracer uptake map as a heterogeneous source and using readily available models for 
clinical and research PET scanners.  These models allow comprehensive simulations of 
the physical performance of a particular PET scanner model and generate the raw data 
that can be used to reconstruct realistic PET image corresponding to any given 
heterogeneous source of activity. To illustrate the validation methodology, a simplified 
approach was used in this study. The 3D map of the intratumoral activity distribution, as 
imaged with autoradiography, was convolved with a 3D Gaussian kernel representative 
of the point spread function measured in the center of the field of view of the Siemens 
Inveon small-animal PET scanner. The FWHM size of the adopted convolution kernel 
was considered appropriate since the reconstructed tumors were generally small (≤1 cm 
 
80 
 
in largest diameter) and the size of the point spread function was shown to be constant 
between the center of the field of view and approximately 15 mm radial offset127, 128 for 
the scanner in question. For larger tumors tumor specimens, convolution with a spatially 
variable Gaussian kernel would have to be implemented. 
The sPET images are based on 3D stacks of autoradiography data. Therefore, 
the accuracy of autoradiography in describing the microscopic uptake of the tracer is 
very important. In this study, 14C-labeled FDG was used to maximize the resolution and 
to simplify the experimental procedures. The effective resolution for thin tissue 
autoradiography with this β- emitter was reported at 100 µm FWHM129. When utilizing 
higher energy positron emitters (e.g. 18F), the resolution of the microscopic tracer 
uptake map may degrade. However, the estimated resolution for 18F autoradiography 
(~200-300 µm) would induce an uncertainty in the actual source position that is less 
than the uncertainty induced by positron travel in PET imaging with a clinical scanner 
(~1.76 mm)68.  
The obvious effect of convolving/blurring autoradiography activity maps is the 
dramatic change in spatial heterogeneity of the tracer uptake (Figure 22). As indicated 
by the overlap analysis between sPET and 3D autoradiography there is little to no 
overlap between segmented volumes for higher activity values. This result is similar to 
previous studies illustrating the averaging effects of PET imaging with FDG69. Clinical 
PET imaging resolution (18F and a 80 cm bore scanner) is about 4-5 mm currently and 
theoretically limited at about 2 mm FWHM because of positron travel and annihilation 
photon non-colinearity{{}}. The inherent blurring effect introduced only by these physical 
properties of PET image acquisition will have a profound effect on the spatial 
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concordance between tracer uptake on PET images and the actual microscopic 
intratumoral uptake, emphasizing the need for experimental validation of PET imaging 
for the purpose of radiotherapy image guidance. 
 
Spatial concordance analysis between FDG uptake and viable tissue 
Based on the illustration involving the analysis of the co-localization between 
FDG high uptake regions and the spatial distribution of viable tissue, it was 
demonstrated that distinct subvolumes indicative of the location of viable tissue can be 
accurately delineated (Figure 23). For example, if the FDG PET image would be 
segmented with a 30% of maximum uptake threshold, more than 80% of the viable 
tissue would be included in the delineated subvolumes. By extending this type of 
analysis over a population of patients, the delineation uncertainty associated with 
clinical segmentation protocols can be directly quantified. This would give a clear 
indication of the efficacy with which biologically targeted radiotherapy can be 
implemented. 
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5. Analysis of spatial concordance between the intratumoral patterns 
of cell proliferation and 18F-fluorothymidine uptake in simulated PET 
images 
5.1 Introduction 
The use of PET imaging for biologically guided radiotherapy has been proposed 
before8. There are different approaches to PET image-guided radiotherapy37, 38. The 
clinical feasibility of 18F-FDG PET-based dose escalation has already been 
demonstrated in clinical trials20, 22.  Similarly, 18F-FLT PET image data can be potentially 
utilized to design biologically-adaptive treatments, where subvolumes characterized by 
active cancer proliferation are targeted with higher doses35-38. 
As reported in previous chapters, there is no current published data 
demonstrating that the intratumoral pattern of FLT uptake as imaged with PET is 
representative of the underlying spatial distribution of active cell proliferation. 
Furthermore, it has been shown that partial volume effect associated with PET imaging 
can potentially degrade the spatial correspondence between in vivo PET images and 
the distribution of the targeted biological pathway69, 70. In chapter 3, it was demonstrated 
that subvolumes delineated on high-resolution DAR images  may not accurately localize 
the  areas of active cell proliferation109. To understand the potential of 18F-FLT PET for 
guiding radiation therapy and improving the clinical outcomes of patients treated with 
FLT-based dose escalation, it is necessary to investigate the spatial correspondence 
between the FLT PET signal and cell proliferation spatial distributions. 
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In chapter 4 a novel PET imaging histopathological validation method for image-
guidance applications was introduced. This method was designed such that it 
circumvents the difficulties associated with registering in vivo PET images with ex vivo 
histopathological images. Using the proposed validation methodology, it was 
demonstrated that while the tracer uptake as seen in sPET image was not as spatially 
heterogeneous as the actual microscopic uptake map, it still provided valuable spatial 
information about the topography of the targeted tumor biological aspect. In this 
chapter, a similar analysis was conducted between a synthetic PET image of FLT 
uptake and the distribution of cell proliferation markers from a whole small-animal tumor 
specimen. 
 
5.2 Methods 
Tumor model and radiotracer 
Human head and neck tumor xenografts (FaDu, SQ20B) were developed in male 
athymic mice as before. This study presents the analysis for a single SQ20B tumor. The 
size of the tumor as measured by caliper was 9.2 mm by 7.3 mm by 6.9 mm. 
14C-labeled 3’-deoxy-3’-F-fluorothymidine was the investigated tracer. It was 
synthesized by Moravek Biochemicals, Inc. (Brea, CA), utilizing an established protocol, 
utilizing 5´-benzoyl-2,3´-anhydrothymidine as a precursor80, 81. The specific activity of the 
compound is 55.7 mCi/ml, and the radiochemical purity is 99.1% as tested with high 
performance liquid chromatography. The 2’-position on the thymidine ring was labeled 
with the 14C isotope. The 14C-labelled FLT compound is chemically identical to the 
previously used 18F-FLT, hence it will be referred to as FLT for the rest of the study 
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(Figure 24). As in chapter 4, the long-lived isotope was utilized for the autoradiography 
resolution advantage that the 14C low-energy decay β- particle offers. 
 
 
Experimental procedure 
The experimental procedures were replicated as presented in chapter 4. The 
single difference was that the bolus injection contained Hoechst (0.4 mg/20-g mouse), 
and at most 1.11 MBq of 14C-FLT. The tissue was embedded utilizing the special 
freezing jig described in the previous chapter. Tissue histochemical processing and 
imaging was conducted as presented before79. From each sampling location, stacks of 
four sequential tissue sections (8 µm) were obtained. All sections were imaged for 
Hoechst staining, images utilized for image registration79. One image was used for DAR 
imaging, while the adjacent sections were utilized to obtain tissue morphology 
information (H&E staining) and the distribution of active cell proliferation (BrdU uptake) 
(Figure 25). There were 56 stacks of 4-sections each obtained from the studied tumor. 
 
Figure 24. Structural similarity between utilized tracers. Left: tracer tagged with 18F FLT, with the positron emitter 
on the ribose ring at position 3’. Right: tracer tagged with 14C at position 2’ on the thymine ring. A stable fluorine 
atom was placed at 3’ position to maintain the biochemical properties of the tracer.   
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As presented before, H&E images were utilized to delineate the extent of the viable 
tissue as a subset of the entire tissue section109. Since there is no a priori information 
about the location and distribution of viable tissue versus necrosis during in vivo PET 
imaging, the region of interest for testing spatial concordance in this project was the 
entire tumor specimen, a union of both viable and non-viable tissue (Figure 26). 
 
Based on the available BrdU images, proliferative cell density images were obtained as 
described in chapter 3. Specifically, the areas of BrdU positive staining were extracted 
 
Figure 26. Section 30 out of 56. Left, H&E and superimposed contours for delineated viable tissue (blue) and 
the outline of the entire tissue section (black). Right, corresponding regions of interest for viable and non-viable 
tumor tissue. Images are on the same scale. 
 
 
Figure 25. Images obtained from sampling location 45 out of 56. H&E for tissue morphology. Hoechst for blood 
flow and diffusion. DAR image of 14C FLT distribution. BrdU uptake as a surrogate for active cell proliferation. All 
images are on the same scale. 
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from the image as a binary mask. The proliferative cell density images were obtained by 
rebinning these masks to 50 µm per pixel, where the fraction of the Brdu positively 
stained area in each rebinned pixel was assigned as the new pixel value. To obtain a 
binary mask of the extent and spatial distribution of cell proliferation, a proliferative cell 
density threshold value was selected such that the resulting set included the majority of 
actively proliferative tumor regions. The maximum proliferative cell density in the studied 
tumor specimen was 40% as defined by the stained area per 50 µm pixel. The threshold 
that was most sensitive to the extent of cell proliferation as imaged with BrdU was 1%. 
To present the variation of the results in the presence of more conservative truth sets, 
5% and 10% thresholds on proliferative cell density were included in the study (Figure 
27).  
 
 
Figure 27. Obtaining truth sets. Left panel: section 30 proliferative cell density grayscale image. Right panel: truth 
sets based on the proliferative cell density image thresholded at different levels.  
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3D reconstruction and PET simulation 
The three-dimensional reconstruction of the intratumoral FLT uptake was 
conducted as presented in the previous chapter. Specifically, all registered images from 
each stack obtained at each sampling location were co-registered to their corresponding 
digital photos of the tissue in the OCT block (Figure 19). 
 
The consistency of the three-dimensional activity pattern of the reconstructed 
autoradiography stack was evaluated by measuring the normalized intensity correlation 
 
Figure 28. Orthoslices sets. All images were normalized to maximum activity and present values between [0, 1]. 
All images are at the same scale. 
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between neighboring slices throughout the tumor volume (mean ± standard deviation = 
0.93 ± 0.04). The sPET images were obtained by convolving the 3D stacked 
autoradiography with a 3D Gaussian kernel representative of the Siemens Inveon small-
animal PET scanner spatial resolution (Figure 28). The spatial correspondence between 
sPET activity map and the original microscopic FLT uptake was evaluated. 
 
Spatial concordance analysis 
Threshold-based and threshold-independent metrics of spatial concordance 
between FLT uptake pattern as seen on the sPET image and the Brdu-defined 
proliferation truth sets were adapted from the 2D analysis presented in chapter 3 to 
three-dimensional analysis. To conduct a spatial concordance analysis based on 
continuous classifiers such as the FLT 3D DAR and sPET images, a binary gold 
standard needs to be established, which will define the classification truth for each 
observation in terms of two mutually exclusive classes: actively proliferating tumor 
versus non-proliferating tumor. 
 
 
Figure 29. Image set at section 30 level. Left panel: Brdu-based truth set (1% proliferative cell density threshold). 
Middle panel: autoradiography. Right panel: synthetic PET image. The autoradiography and sPET images were 
normalized to the maximum value in the 3D volume. All images are on the same scale. 
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As mentioned before, the gold standard for the extent and spatial distribution of cell 
proliferation are the BrdU-defined truth sets (Figure 29). Both DAR and sPET images of 
FLT uptake were thresholded to obtain instances of measurement sets (observations).  
Varying threshold values were applied to these image sets and the resulting 
segmentation measurement sets were directly compared to the gold standard. For each 
observation, i.e. for each threshold level applied to either the 3D DAR or sPET image, a 
contingency table was created as in chapter 3 (Figure 12). By varying the threshold 
values over all the available activity levels in the FLT uptake images, the sensitivity and 
specificity of the classification method could be determined as a function of threshold 
level 109. The ROC curves were plotted and the area under the curve was measured as 
presented before. Furthermore, for each instance of the measurement sets, the Dice 
coefficients were also calculated based on the contingency table metrics. Both ROC 
curve analysis and Dice coefficient curves were plotted for truth sets obtained for 1%, 
5%, and 10% proliferation cell density.  
 Based on the Dice curves a threshold level was established for which the Dice 
coefficient reached a maximum value, indicating maximum amount of spatial 
information retrieved by the FLT-based segmentation volume about the truth set shape 
and extent. For this particular threshold value, the following metrics were computed 
based on the corresponding contingency table (Figure 12): sensitivity, specificity, 
accuracy. All these metrics will be discussed in the following sections in terms of the 
studied classification problem: FLT thresholding classifying actively proliferating or non-
proliferative pixels within the volume of interest. 
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5.3 Results 
Correspondence between FLT uptake in 3D autoradiography data and sPET 
image set 
As illustrated by the orthoslices in Figure 28, the convolution process significantly 
affects the spatial heterogeneity of the FLT uptake. In order to investigate the 
correspondence between the pattern of FLT uptake as recorded in the 3D 
autoradiography and sPET, the image sets were normalized to maximum activity and 
thresholded at different thresholds across the [0, 1] range (Figure 30).  
 
Since the sPET image is inherently registered to the autoradiography set from which it 
was created, the discrepancies between sPET images and the underlying microscopic 
uptake of FLT were directly attributed to the finite resolution of PET imaging. While 
distinct tumor subvolumes can be delineated in both image sets (Figure 31), the 
 
Figure 30. Plot of Dice coefficient values as a function of threshold values applied to normalized FLT uptake (DAR 
and sPET) images. The red line emphasizes the overlap between DAR and sPET segmentation volumes for 30% of 
max activity threshold. This threshold produces a sPET segmentation volume that best represents the spatial extent 
of cell proliferation. 
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mentioned difference becomes important when regions of high tracer uptake of the 
tumor are considered for targeting. It is at these conservative threshold values where 
the overlap between the segmented volumes on FLT and DAR coincide the least 
(Figure 30), as indicated by Dice coefficient values: 0.037 at 70% of maximum activity, 
0.33 at 50%, 0.6 at 30%, and 0.83 at 10%. 
 
 
Spatial concordance analysis between FLT uptake and cell proliferation 
The observable loss in spatial heterogeneity of the FLT uptake pattern imaged 
with sPET vs. the 3D autoradiography was consistent with the ROC analysis results. 
Since the 3D DAR imaging resolution is higher, smaller details of the spatial distribution 
of cell proliferation could be resolved. Therefore, when thresholding FLT 3D DAR 
images to retrieve the spatial extent of active cell proliferation, the AUC values were 
higher than when sPET thresholding was utilized (Figure 32). This result was consistent 
over all the utilized truth sets. The high AUC values in both cases are a direct 
 
Figure 31. Rendered tissue outline with segmentation volumes. A. 3D reconstructed autoradiography. B. sPET. 
Threshold values represent percent of maximum intensity. Images are at the same scale. 
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confirmation that higher uptake values coincide spatially with actively proliferating tumor 
subvolumes, for both DAR and sPET image sets. 
 
 
Figure 33. Dice overlap analysis between segmented volumes on FLT uptake images and the BrdU-defined truth set, as 
a function of utilized FLT threshold value. Different arrows indicate the threshold value for which a maximum Dice 
coefficient value occurred. Different truth sets were used as gold standard for classification results: 1%, 5%, and 10% 
proliferative cell density. 
 
 
Figure 32. ROC analysis of FLT uptake image segmentation as a classifier of the extent and spatial distribution of cell 
proliferation. Different truth sets were used as gold standard for classification results: 1%, 5%, and 10% proliferative 
cell density. Red dotted line is indicative of random chance. An AUC value closing unity is indicative of perfect 
sensitivity and specificity of the investigated classification method given a defined truth set. 
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The spatial concordance between tumor regions with high FLT uptake and 
actively proliferative subvolumes was also evident from the Dice analysis. While 
creating increasingly conservative truth sets, the FLT uptake threshold at which the 
maximum spatial information about the underlying cell proliferation pattern was retrieved 
was also increasingly higher (Figure 33), for both DAR and sPET image sets. The 
values of the maximum Dice coefficients for the 1%, 5%, and 10% were: 0.72, 0.52, and 
0.24 for 3D DAR, and 0.6, 0.38, and 0.15 for sPET respectively. 
 
FLT based delineation of actively proliferating subvolumes 
As indicated in Figure 33, thresholding the sPET image at 30% of maximum 
intensity creates a segmentation volume that was most accurate in describing the 
underlying spatial distribution of cell proliferation for the BrdU-based truth set. The 
resulting subvolume covered 74% of the truth set obtained with 1% proliferative cell 
density threshold, presenting good sensitivity to the extent of active cell proliferation. 
 
The overall specificity with which the delineated subvolume identified positive pixels in 
the truth set was 0.62, indicating average ability to identify the negative pixels in the 
 
Figure 34. Sequential sections through tumor specimen, presenting BrdU-based truth set obtained with 1% 
proliferative cell density threshold. The colored lines present activity iso-lines from the sPET image sequence. 
Thresholds are percent of maximum activity. All images are at the same scale. 
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truth set. This aspect was also emphasized by a classification accuracy of 0.66 for the 
utilized truth set. Figure 34 presents the 1% truth set at different locations throughout 
the tumor volume. The illustrated overlap between the 30% threshold iso-line and the 
truth set provides for a visual confirmation of the sensitivity and specificity of the 
method. 
 
5.4 Discussion 
Non-invasive imaging of active cell proliferation has been proposed for 
radiotherapy guidance. Taking advantage of the biochemical properties of FLT and the 
long half-life of 18F, PET imaging with this tracer has been receiving a lot of attention for 
treatment adaptation in biologically guided radiotherapy37. Nevertheless, the potential 
impact of PET imaging resolution limitations may compromise the accuracy of 
delineating tumor subvolumes that are to be targeted with increased doses. Each image 
voxel may contain independent regions of active cell proliferation, and an unaccounted 
combination of necrotic tissue, viable non-proliferating and viable actively proliferating 
subvolumes (Figure 4). 
In this study, the spatial concordance between FLT uptake pattern as imaged 
with PET and microenvironmental distribution of active cell proliferation was assessed. 
Synthetic PET images were obtained from the reconstructed microscopic pattern of FLT 
uptake (Figure 28) as described in chapter 4. The extent and spatial distribution of 
active cell proliferation were defined based on the uptake of BrdU, an acknowledged 
exogenous marker of cell proliferation (Figure 27) as described in chapter 3. The two 
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data sets were accurately co-registered using techniques previously described in this 
work.  
The spatial concordance analysis was conducted on imaging data obtained from 
tumor xenografts developed in immuno-compromised mice. Since animal tumor models 
are characterized by growth dynamics, morphology and vascularization different from 
those encountered in human tumors, the FLT uptake images utilized throughout this 
validation study are not likely to be representative of the FLT uptake images from 
human patients. However, this study is not aimed at making inferences about the 
differences between FLT uptake in animal and human tumors. The animal tumors 
utilized in this study were characterized by highly heterogeneous microenvironments 
consisting of a wide range of physiological states. Correspondingly, the FLT uptake 
pattern of observed in DAR imaging as well as that of BrdU nuclear incorporation 
observed in IFM imaging from these tumors were spatially heterogeneous (Figure 25). 
Hence, they were valid experimental platforms for assessing spatial concordance 
between the two imaging sets. Furthermore, they were perfect tools to develop and 
optimize PET tracer validation methodologies that may be readily translated to human 
specimens.  
Another important consideration is that there are physiological differences 
between animal and human tumors that directly affect the absolute levels of FLT 
intratumoral uptake. The levels of endogenous thymidine are significantly higher in 
rodents51-53. Correspondingly, FLT competes with the serum thymidine for all stages in 
the cellular incorporation mechanisms. Therefore, it is expected that the FLT uptake is 
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less than the levels encountered in human tumors. However, these factors do not affect 
the investigation of spatial characteristics of intratumoral uptake of FLT.  
Furthermore, FLT is metabolized in human tumors via glucoronidation (liver 
metabolism) within 60 minutes post tracer injection. This does not occur in rodents 
which may influence the absolute uptake levels of FLT in rodents. However, this study 
aims at analyzing the spatial pattern of FLT entrapment in the studied tumors and its 
correspondence to the spatial pattern of cell proliferation. Related to the FLT 
metabolism problem, another potential contention with the presented validation 
methodology would be that the sPET images are representative of static PET imaging. 
While it has been shown that kinetic analysis of dynamic FLT PET data is needed in 
some cases to accurately quantify FLT uptake53, 130, good agreement has been 
demonstrated between dynamic PET uptake data and the standard uptake value 
obtained 45-60 minutes after injection using static PET acquisition55, 131. Furthermore, 
FLT standard uptake value has been shown to be stable between 55 and 100 minutes 
post injection132. These studies suggest that static FLT PET imaging can provide 
accurate uptake data in a less logistically demanding approach compared to dynamic 
scanning. Therefore, the synthetic PET images developed from the intratumoral FLT 
microscopic uptake after 80 minutes of uptake are representative of actual static PET 
images corresponding to the investigated tumor specimen. 
For the single tumor specimen utilized in this study, the microscopic FLT uptake 
pattern as imaged with 3D DAR is spatially concordant with actively proliferative tumor 
subvolumes. Furthermore, the macroscopic pattern of FLT uptake imaged with sPET, 
while significantly different than the 3D DAR pattern, it still provides spatial information 
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about the underlying spatial distribution of cell proliferation. By expanding the analysis 
over a larger set of tumor specimens, the delineation uncertainty associated with 
different segmentation protocols could be quantified and optimal cell-line specific 
threshold values could be determined to delineate subvolume characterized by active 
cell proliferation. 
Dice coefficient curve analysis presented a distinct feature, consistent over all the 
utilized truth sets, for both DAR and sPET image sets. The presence of a peak in the 
Dice coefficient variation over the given thresholds values, a value that was distinct from 
the all-inclusive minimum threshold, indicated the existence of a specific sPET/DAR 
threshold value that maximized the number of correctly classified voxels (Figure 33).  
When introducing more conservative BrdU-defined truth sets (5%, 10%), the Dice peak 
moved towards higher threshold levels, confirming that areas that contained higher FLT 
uptake values, also contained more actively proliferating cells. This result is a direct 
confirmation of the spatial concordance between the pattern of FLT uptake and the 
spatial distribution of cell proliferation for the specimen used in this illustrative example. 
The flatter Dice curves recorded for sPET images are a result of the lower resolution of 
the imaging modality. The large features in the sPET FLT uptake pattern could not 
accurately resolve all proliferation spatial features (Figure 28). The fraction of incorrectly 
classified pixels was always greater in the case of the sPET image set due to the 
mismatch in imaging resolution, affecting the slope of the Dice curve before and after 
the maximum value. This effect was also evident when more conservative truth sets 
were utilized within the same imaging modality. Since the same set of segmentation 
volumes were utilized to determine increasingly more conservative truth sets, a larger 
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fraction of incorrectly classified pixels were included in the delineated subvolumes, 
creating a flatter Dice curve and lower values for the maximum. 
The high AUC values obtained for the single investigated tumor specimen, 
suggest that segmenting images of FLT uptake is an accurate method of distinguishing 
between proliferating and non-proliferating voxels, as defined by the BrdU truth sets. In 
Figure 32, the ROC curves and corresponding AUC values were presented. While not 
as high as when the 3D DAR FLT uptake image set was utilized for determination of the 
extent and spatial distribution of cell proliferation, the sPET AUC values were still 
indicative of a good classification method105. As in the Dice analysis, the averaging 
effect of PET imaging decreased the specificity with which the spatial pattern of active 
cell proliferation was retrieved, increasing the false positive pixel rate of detection, and 
decreasing the overall AUC value. 
The threshold-based analysis for 30% of maximum activity sPET threshold 
indicated good sensitivity, average specificity, and a resulting mediocre accuracy of FLT 
sPET segmentation in retrieving the spatial extent and spatial distribution of the given 
truth. Figure 34 illustrates those aspects, as the 30% iso-line includes some of the truth 
set at all times, while it does not manage to resolve the disseminated non-proliferating 
regions. If the tumor subvolume delineated based on the 30% iso-line would be used in 
biologically adaptive radiotherapy (Figure 2), it would contain the majority of the defined 
actively proliferating area (74%), while encompassing only 50% of the total delineated 
tumor volume. Depending on the shape of the resulting subvolume, an escalated dose 
could be accurately delivered to this subvolume while limiting the surrounding normal 
tissue exposure133. In conclusion, while the tracer uptake as seen in FLT sPET image 
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was not as spatially heterogeneous as the actual microscopic uptake map, it still 
provided valuable spatial information about the topography of the targeted biological 
feature.  
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6. Conclusions 
The dissertation research presented herein was focused on histopathological 
validation of FLT PET imaging for biologically-guided radiotherapy. Two specific aims 
were set to reach the thesis goal. First, the spatial concordance between the FLT 
uptake pattern and the spatial distribution of cell proliferation was analyzed at a 
microscopic level. The results of the study presented in chapter 3 provided the first set 
of experimental data validating that in vivo FLT microscopic uptake coincide with areas 
of active cell proliferation as imaged with conventional immuno-fluorescence methods. 
In addition, this study emphasized the need for histopathological validation of FLT PET 
for image-guidance applications since it demonstrated that even high-resolution imaging 
modalities such as DAR could not consistently and accurately retrieve the extent and 
spatial distribution of proliferative tumor subvolumes when cell proliferation is highly 
dispersed throughout the tumor. 
The second specific aim of the thesis addressed the development and 
implementation of new histopathological validation tools to analyze spatial concordance 
between volumes segmented on FLT simulated PET images and the three dimensional 
spatial distribution of cell proliferation markers. Since there were no standardized 
methods applicable towards the goals of this thesis, a novel approach of 
histopathological validation of PET imaging for image-guidance in radiotherapy was 
developed and tested in chapter 4. By relying on autoradiography-based simulated PET 
images generated in such a way as to correctly represent 3D tracer distributions, the 
validation workflow was reversed, circumventing problems associated with registration 
of non-invasive in vivo PET images and ex vivo histopathological images. Furthermore, 
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this methodology was developed with the end-goal of direct translation to validation 
studies utilizing human tumor specimens, and for any combination of PET tracer vs. 
targeted tumor biology. Chapter 2 presented a novel multimodality image co-registration 
workflow that minimized the geometrical misalignments between autoradiography and 
microscopy images acquired from sequential tissue sections. By utilizing deformable 
image registration and histopathological images of blood flow as inter-section spatial 
correspondences, the images acquired from up to four different sequential tissue 
sections could be presented as if obtained from the same location. The improvement in 
registration accuracy could further advance correlative studies of the 
microenvironmental factors governing PET tracer intratumoral distribution as well as the 
studies aimed at investigation of spatial co-localization of different aspects of tumor 
biology that can be revealed by combination of autoradiography and/or microscopy 
imaging.  
The research work described here as a whole, was aimed at filling a major gap in 
data supporting the use of FLT PET for the purpose of imaging the spatial pattern of 
cancer cell proliferation. While much work remains to be done, the advancements 
introduced by this thesis will hopefully press forward the research in this aspect of 
biologically adaptive radiotherapy and open new and improved opportunities for cancer 
patient care. 
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